Electronic Supplementary Material (ESI) for Organic & Biomolecular Chemistry. This journal is © The Royal Society of Chemistry 2024

# Borrowing Hydrogen *C*-alkylation with secondary saturated heterocyclic alcohols

Jordan François, Maïwenn Jacolot,\* Florence Popowycz\*

INSA Lyon, Université Lyon 1, CNRS, CPE Lyon, UMR 5246, ICBMS. 1 rue Victor Grignard, 69621, Villeurbanne Cedex, France.

# **Supporting information**

# Table of contents

General information	
General procedure A for the synthesis of 4-alkylated 3-hydroxyTHF	4
General procedure B for the metal catalyzed BH C-C coupling	4
General procedure C for the sequential C-N / C-C coupling	5
General procedure D for sequence Ph* cleave / amidation	5
General procedure E for the Ph* cleavage / esterification	5
General procedure F for the sequential BH C-C coupling / Ph* cleavage / esterification	6
Preparation of the starting materials	6
5-Methyltetrahydrofuran-3-ol 2b [29848-43-9]	6
2-Methyltetrahydrofuran-3-ol 2c [1643965-13-2]	7
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-Methyltetrahydrofuran-3-ol 2d [387357-58-6]	7
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-Ethyltetrahydrofuran-3-ol 2e [387357-51-9]	8
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-Propyltetrahydrofuran-3-ol 2f [2956413-65-1] [1999335-59-9]	8
(±)-(3R,4S)-4-Isopropyltetrahydrofuran-3-ol 2g [321903-37-1]	8
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-Cyclohexyltetrahydrofuran-3-ol 2h [1996554-90-5]	8
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-Benzyltetrahydrofuran-3-ol 2i [321903-36-0]	9
(±)-(3 <i>S</i> ,4 <i>S</i> )-4-Methoxytetrahydrofuran-3-ol 2k [876026-49-2]	9
(±)-(3 <i>R</i> ,4 <i>S</i> )-4-(Dimethylamino)tetrahydrofuran-3-ol 2l [30197-51-4]	9
(2R,4r,6S)-2,6-Dimethyltetrahydro-2H-pyran-4-ol 2n [33747-09-0]	10
(+/-)-(3R,4S)-1-Benzyl-4-methylpyrrolidin-3-ol 4g	10
1-Benzylpiperidin-3-ol 4i [14813-01-5]	11
1-Benzyl-1,2,3,4-tetrahydroquinolin-4-ol 4j [3954-48-1]	11
BH C-C coupling with secondary O- and N-heterocyclic alcohols	12
1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone 3a [2956413-69-5]	12
2-(5-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3b [2956413-71-9/2956413-70-8]	12
2-(2-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3c	13
2-(4-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3d Ru-MACHO [2956413-73-1/29564	
2-(4-Ethyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3e [2956413-75-3] [2956413-74-2]	14
1-(2,3,4,5,6-Pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethenone 3f [2956413-75-3/2956413-74-2]	14
2-(5-2-(4-lsopropyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3g	15
2-(4-Cyclohexyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3h	15
2-(4-Benzyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3i	16
2-((3 <i>R</i> ,6 <i>S</i> )-6-( <i>Tert</i> -butoxy)hexahydrofuro[3,2- <i>b</i> ]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3j <sup>5</sup>	
(±)-2-((3R,4R)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3k [2956413-76-4]	
2-(4-(Dimethylamino)tetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3l	
1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydro-2H-pyran-4-yl)ethanone 3m	18
2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3n	

2-(1-Benzylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5a	19
2-(1-(4-Methylbenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5b	19
2-(1-(3-Methoxybenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5c	19
1-(2,3,4,5,6-Pentamethylphenyl)-2-(1-(4-(trifluoromethyl)benzyl)pyrrolidin-3-yl)ethanone 5d	20
2-(1-(4-Fluorobenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5e	20
1-(2,3,4,5,6-pentamethylphenyl)-2-(1-phenethylpyrrolidin-3-yl)ethanone 5f	21
2-(1-Benzyl-4-methylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5g	21
2-(1-Benzylpiperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5h [2075811-80-0]	22
2-(1-Benzylpiperidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethenone 5i	22
2-(1-Benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5j	22
1-(2,3,4,5,6-pentamethylphenyl)-2-(piperidin-4-yl)ethanone 5k	23
2-(1-(2-Fluorobenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5l	23
2-(1-Hexylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5m	24
2-(1-(4-Fluorobenzyl)piperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5n	24
2-(1-Hexylpiperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 50	25
Ph* Cleavage and post-functionalization	25
2-(Tetrahydrofuran-3-yl)acetic acid 6a [138498-97-2]	25
N-(4-Methylbenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7a	26
N-(4-Iodobenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7b	26
N-(4-Methoxybenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7c	26
N-Hexyl-2-(tetrahydrofuran-3-yl)acetamide 7d	27
2-(4-Benzyltetrahydrofuran-3-yl)- <i>N</i> -benzylacetamide 7e	27
2-(4-Benzyltetrahydrofuran-3-yl)-N-(4-methylbenzyl)acetamide 7f	28
(±)-N-(4-iodobenzyl)-2-((3R,4S)-4-propyltetrahydrofuran-3-yl)acetamide7g	28
2-((3 <i>R</i> ,6 <i>S</i> )-6-Hydroxyhexahydrofuro[3,2- <i>b</i> ]furan-3-yl)- <i>N</i> -(4-iodobenzyl)acetamide 7h	29
2-(1-Benzylpyrrolidin-3-yl)- <i>N</i> -(4-methylbenzyl)acetamide 7i	29
2-(1-Benzylpiperidin-4-yl)-N-(4-methylbenzyl)acetamide 7j	29
Methyl 2-(4-benzyltetrahydrofuran-3-yl)acetate 8a	30
Methyl 2-(1-benzylpyrrolidin-3-yl)acetate 8b [95274-12-7]	30
Methyl 2-(1-Benzylpiperidin-4-yl)acetate 8c	31
4-(2-Methoxy-2-oxoethyl)piperidinium chloride 8d [81270-37-3]	31
<sup>1</sup> H, <sup>13</sup> C NMR spectra and Mass Analysis	31
Single-Crystal X-ray diffraction	155
(±)-2-((3R,4R)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3k	155
(±)-N-(4-iodobenzyl)-2-((3R,4S)-4-propyltetrahydrofuran-3-yl)acetamide7g	157

# **General information**

Reagents and solvents were supplied by Aldrich, Alfa Aesar and TCI Chemicals. NMR spectra were recorded on a Bruker 300 ( $^{1}$ H: 300 MHz), Bruker 400 ( $^{1}$ H: 400 MHz;  $^{13}$ C: 100 MHz) spectrometers at 298 K, using CDCl<sub>3</sub> as solvent. The chemical shifts ( $\delta$ , ppm) are referenced to the residual solvent peak and coupling constants (J) are reported in the standard fashion. The following abbreviations are used to explain the multiplicities: s = singlet, d = doublet, t = triplet, dd = doublet of doublets, dt = doublet of triplets, dt = doubl

#### IUPAC Nomenclature for synthetized O and N- saturated heterocycles

# **General procedures**

#### General procedure A for the synthesis of 4-alkylated 3-hydroxyTHF

Grignard reagent (1.5 to 2.0 eq.) was added to a solution of CuI (20 mol%) at X °C under Ar. After 30 minutes, 3,6-dioxabicyclo[3.1.0]hexane (1.0 eq.) was added and the mixture was then allowed to warm up to rt and stirred for 18 h. The mixture obtained was quenched with an aqueous saturated NH<sub>4</sub>Cl solution (15 mL). Then, diluted with water (15 mL) and extracted with diethyl ether (5 x 30 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. Purification by flash column chromatography packed with silica afforded the title compound.

# General procedure B for the metal catalyzed BH C-C coupling

To a 10 mL Biotage® microwave vial equipped with a stirrer bar were introduced **alcohol** (1.0 eq.), pentamethylacetophenone (1.1 eq.), base (2.0 eq.), **catalyst** (5 mol% of Metal) and 1,3,5-trimethoxybenzene as standard in the open vessel. The vial was placed under inert atmosphere by performing 3 cycles vacuum/ $N_2$ . Then, toluene [1.0 M] was introduced and the vial was sealed with a microwave vial cap. The vial was heated at 120 °C for 24 h in a preheated tray. The mixture was cooled down to room temperature and few drops of water (100  $\mu$ L) were added. The reaction vessel was washed with DCM (10 mL) and concentrated under reduced pressure. Purification by flash column chromatography packed with silica afforded the title compound **3** or **5**.

#### General procedure C for the sequential C-N / C-C coupling

To a 10 mL Biotage® microwave vial equipped with a stirrer bar were introduced **the triol** (1.2 eq.), KO<sup>t</sup>Bu (2 mol%), **Ir-2** (2 mol%) and 1,3,5-trimethoxybenzene (0.33 eq.) as standard in the open vessel. The vial was placed under inert atmosphere by performing 3 cycles vac/N<sub>2</sub>. Then, *tert*-amyl alcohol [1M] followed by the corresponding amine (1.0 eq.) were added to the reaction mixture and the vial was sealed with a microwave vial cap. The vial was heated at 100 °C for 7 h in a preheated metal tray. The crude mixture was cooled down to rt and water (20 mL) was added. The product was extracted thrice with EtOAc (3 x 15 mL) and once with DCM (15 mL). The organic layer was then dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. Catalyst **Ir-2** (5 mol%), pentamethylacetophenone (1.1 eq.) and KO<sup>t</sup>Bu (2.0 eq.) were introduced with the crude mixture in a 10 mL Biotage® microwave vial equipped with a stirrer bar. The vial was placed under inert atmosphere by performing 3 cycles vac/N<sub>2</sub>. Then, *tert*-amyl alcohol [1M] followed by **the amine** (1.0 eq.) were added to the reaction mixture and the vial was sealed with a microwave vial cap. The vial was heated at 120 °C for 24 h in a preheated metal tray. The crude mixture was cooled down to rt, concentrated under reduced pressure and purification by flash column chromatography packed with silica afforded the title compound **5**.

# General procedure D for sequence Ph\* cleave / amidation

X = O or NR

To a solution of **the alkylated ketone 3** or **5** (1.0 eq.) in HFIP (0.1 M) in a MW vial, 37% aqueous HCl (12 M, 150  $\mu$ L per mL of HFIP) was added dropwise to the solution and the vial was rapidly sealed with a cap. The reaction mixture was then heated at 65 °C in a preheated tray and stirred for 24 h. After complete conversion, the mixture was cooled to rt and H<sub>2</sub>O (5 mL) was added. The solution obtained was further stirred for 5 min. The product was extracted with DCM (3 x 5 mL). The organic phases were combined and washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure.

The obtained residue was dissolved in toluene (0.5 M). Boric acid (0.3 eq.) and the amine (1.0 eq.) were introduced sequentially in the open vessel. Then, the mixture was refluxed using a Dean-Stark apparatus. for 24 h. After cooling down to rt, water (10 mL) and EtOAc (10 mL) were added. The aqueous phase was extracted with EtOAc (3 x 10 mL). The organic phases were combined, washed with an aqueous saturated solution of NaHCO<sub>3</sub> (20 mL), brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated in vacuo. Purification by flash column chromatography packed with silica afforded the title compound **7**.

#### General procedure E for the Ph\* cleavage / esterification


X = O or NR

To a solution of the **alkylated ketone 3** or **5** (1.0 eq.) in HFIP (0.1 M) in a MW vial, 37% aqueous HCl (12 M, 150  $\mu$ L per mL of HFIP) was added dropwise to the solution and the vial was rapidly sealed with a cap. The reaction mixture was then heated at 65 °C in a preheated tray and stirred for 24 h. After complete conversion, the mixture was cooled to rt and H<sub>2</sub>O (5 mL) was added. The solution obtained was further stirred for 5 min. The product was extracted with DCM (3 x 5 mL). The organic phases were combined and washed with brine (10 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure.

The obtained residue was dissolved in MeOH (0.5 M) and cooled to -50 °C. Thionyl chloride (1.1 eq.) was added dropwise to the mixture and stirred for 18 h at rt Then, the solution was treated with an aqueous saturated NaHCO<sub>3</sub> solution (10 mL) and

the aqueous layer was extracted with DCM (3 x 10 mL). The organic phases were combined, washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. Filtration on a silica/celite® pad afforded the title compound **8**.

# General procedure F for the sequential BH C-C coupling / Ph\* cleavage / esterification



To a 10 mL Biotage $^{\circ}$  microwave vial equipped with a stirrer bar were introduced **piperidinol derivative** (1.0 eq.), pentamethylacetophenone **1** (1.1 eq.), base (2.0 eq.), **Ir-1** (5 mol%) and 1,3,5-trimethoxybenzene as standard in the open vessel. The vial was placed under inert atmosphere by performing 3 cycles vacuum/N<sub>2</sub>. Then, toluene [1.0 M] was introduced and the vial was sealed with a microwave vial cap. The vial was heated at 120  $^{\circ}$ C for 24 h in a preheated tray. The mixture was cooled down to room temperature and few drops of water (100  $\mu$ L) were added. The reaction vessel was washed with DCM (10 mL) and concentrated under reduced pressure.

The crude ketone was then transferred into a MW vials, dissolved in HFIP (0.1 M) and 37% aqueous HCl (30-40 eq.) was added dropwise. The vial was rapidly sealed and the reaction mixture was heated at 65 °C in a preheated tray for 24 h. After complete conversion, the mixture was cooled to rt and  $H_2O$  (5 mL) was added. The solution obtained was further stirred for 5 min. The product was extracted with DCM (3 x 5 mL). The organic phases were combined and washed with brine (10 mL), dried over  $Na_2SO_4$ , filtered and concentrated under reduced pressure.

The obtained residue was dissolved in MeOH (0.5 M) and cooled to -50 °C. Thionyl chloride (1.1 eq.) was added dropwise to the mixture and stirred for 18 h at rt Then, the solution was treated with an aqueous saturated NaHCO<sub>3</sub> solution (10 mL) and the aqueous layer was extracted with DCM (3 x 10 mL). The organic phases were combined, washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under reduced pressure. Filtration on a silica/celite pad afforded the title compound 8.

# Preparation of the starting materials

#### 5-Methyltetrahydrofuran-3-ol 2b [29848-43-9]

In a 50 mL round-bottom flask, under  $N_2$ , was introduced 4-penten-2-ol (0.50 g, 5.81 mmol, 1.0 eq.) and  $Et_3N$  (2.30 mL, 8.72 mmol, 1.5 eq.) in anhydrous DCM (15 mL) at 0 °C. Then, p-toluenesulfonyl chloride (1.66 g, 8.72 mmol, 1.5 eq.) and DMAP (0.07 g, 0.58 mmol, 10 mol%) were added sequentially and the reaction mixture was allowed to warm up to rt and stirred overnight. After completion of the reaction, an aqueous saturated solution of  $NH_4Cl$  (30 mL) was added and the aqueous phase was extracted with DCM (3 x 10 mL). The organic phases were washed with a brine solution (50 mL), dried over  $Na_2SO_4$ , filtrated and concentrated under reduced pressure. Filtration through  $SiO_2$  with DCM gave 4-penten-2-tosylate as a colorless oil (1.36 g, 97%). CAS: 52753-86-3. NMR spectra were consistent with the literature.<sup>4</sup>

To a stirred solution of  $OsO_4$  (0.05 mL,  $4\%wt/H_2O$ , 0.5 mol%) and NMO (194 mg, 1.66 mmol, 1.0 eq.) in t-BuOH/H<sub>2</sub>O (15 mL, 1:1) at 0 °C was added 4-penten-2-tosylate (400 mg, 1.66 mmol, 1.0 eq.). The resulting solution was allowed to warm up to rt and was stirred for 24 h. After the addition of sodium sulfite (800 mg), the reaction mixture was stirred for an additional 1 h. The mixture was extracted with EtOAc (3 x 10 mL) and the organic layers were dried over Na<sub>2</sub>SO<sub>4</sub>, filtrated and concentrated. The crude mixture was purified by flash column chromatography (SiO<sub>2</sub>, Pentane/EtOAc, 1:1) and gave 5-methyltetrahydrofuran-3-ol **2b** as a mixture of two diastereoisomers (117 mg, 70%, dr 57:43 determined by  $^1$ H NMR).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.26 (d, J = 6.1, 3H, CH<sub>3</sub>, dia 1), 1.35 (d, J = 6.1, 3H, CH<sub>3</sub>, dia 2), 1.48 (dddd, J = 13.4, 7.5, 3.0, 1.3, 1H, H<sub>4</sub>, dia 2), 1.60 (ddd, J = 13.3, 9.7, 5.6, 1H, H<sub>4</sub>, dia 1), 1.77 (bd, J = 4.4, 1H, OH, dia 1), 1.81 (bd, J = 6.4, 1H, OH, dia 2), 2.00 (app ddt, J = 13.3, 5.5, 1.2, 1H, H<sub>4</sub>, dia 1), 2.37 (ddd, J = 13.4, 7.5, 6.7, 1H, H<sub>4</sub>, dia 2), 3.63–3.72 (m, 2H, 2 H<sub>2</sub>, dia 1 and 2), 3.85

(app. dt, J = 10.0, 1.6, 1H, H<sub>2</sub>, dia 2), 3.95 (app tq, J = 7.5, 6.2, 1H, H<sub>5</sub>, dia 2), 4.06 (dd, J = 9.9, 4.6, 1H, H<sub>2</sub>, dia 1), 4.18–4.31 (m, 1H, H<sub>4</sub>, dia 1), 4.45 (bs, 1H, H<sub>1</sub>, dia 2), 4.51 (bs, 1H, H<sub>1</sub>, dia 1).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 20.7 ( $\underline{C}$ H<sub>3</sub>, dia 1), 21.8 ( $\underline{C}$ H<sub>3</sub>, dia 2), 43.2 ( $\underline{C}$ 5, dia 2), 43.6 ( $\underline{C}$ 5, dia 1), 73.1 ( $\underline{C}$ 1, dia 1), 73.2 ( $\underline{C}$ 1, dia 2), 74.1 ( $\underline{C}$ 4, dia 1), 75.2 ( $\underline{C}$ 4, dia 2), 75.6 ( $\underline{C}$ 5, dia 2).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for C<sub>5</sub>H<sub>10</sub>NaO<sub>2</sub>: 125.0573, found 125.0575.

#### 2-Methyltetrahydrofuran-3-ol 2c [1643965-13-2]

OsO<sub>4</sub> (H<sub>2</sub>O, 4%), 0.5 mol%, K<sub>3</sub>Fe(CN)<sub>6</sub>, 3 eq., K<sub>2</sub>CO<sub>3</sub>, 3 eq., (DHQ)<sub>2</sub>PHAL, 1 mol%

OMS

OMS

OMS

$$\frac{K_2CO_3}{BuOH/H_2O}$$
 (1:1), 0°C, 24 h

 $\frac{C}{A}$  (2c dr > 99:1

(E)-3-Pentenol (0.70 g, 8.1 mmol, 1.0 eq.) and Et<sub>3</sub>N (1.5 mL, 10.6 mmol 1.3 eq.) were dissolved in anhydrous DCM (15 mL) and cooled to 0 °C under Ar. The solution was stirred for 10 min and methanesulfuonyl chloride (0.8 mL, 9.8 mmol, 1.2 eq.) was added dropwise. The reaction mixture was allowed to warm up to rt and stirred for 18 h. After complete reaction (TLC monitoring), the solution was cooled to 0 °C and HCl (2N, 20 mL) was added carefully. The aqueous layer was then extracted with DCM (3 x 50 mL). The organic layers were combined, washed with brine, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The product (E)-pent-3-en-1-yl mesylate, obtained as a yellow oil (1.25g, 93%), was used for the next step without further purification.

To a well-stirred solution of  $K_3Fe(CN)_6$  (2.08 g, 6.32 mmol, 3.0 eq.),  $K_2CO_3$  (0.87 g, 6.32 mmol, 3.0 eq.), and (DHQ)<sub>2</sub>PHAL (16 mg, 0.02 mmol, 1 mol%) in t-BuOH/H<sub>2</sub>O (20 mL 1:1 v/v) at 0 °C was added OsO<sub>4</sub> (64 µL, 4wt%/H<sub>2</sub>O, 0.011 mmol, 0.5 mol%). (*E*)-Pent-3-en-1-yl mesylate (0.35 g, 2.11 mmol, 1.0 eq.) was added dropwise and the reaction mixture stirred at 0 °C for 24 h. Next, solid sodium sulfite (1 g) was added, and the mixture was stirred for an additional hour at 0 °C. The solution obtained was diluted with DCM (15 mL) and after separation of layers, the aqueous phase was extracted with DCM (3 x 10 mL). The organic layers were combined, washed with brine (20 mL), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The crude obtained was purified by flash column chromatography on silica gel (solid load, pentane/EtOAc, 1/1) to provide 2-methyltetrahydrofuran-3-ol **2c** as a colorless oil (103 mg, 48%, dr >99:1 determined by <sup>1</sup>H NMR).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.27 (d, J = 6.4, 3H, Me), 1.94 (dddd, J = 13.5, 8.0, 5.1, 1.6, 1H, H<sub>4</sub>), 2.22 (dddd, J = 13.5, 9.3, 7.3, 5.4, 1H, H<sub>4</sub>), 3.67–3.80 (m, 2H, H<sub>2</sub>, H<sub>5</sub>), 3.97–4.09 (m, 1H, H<sub>5</sub>), 4.17 (ddd, J = 5.4, 3.2, 1.6, 1H, H<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  14.0 (C<sub>Me</sub>), 35.9 (C<sub>4</sub>), 65.8 (C<sub>5</sub>), 73.5 (C<sub>3</sub>), 78.7 (C<sub>2</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_5H_{10}O_2Na$ : 125.0573, found, 125.0571.

### (±)-(3R,4S)-4-Methyltetrahydrofuran-3-ol 2d [387357-58-6]



**Methyl magnesium bromide** (3 M in THF, 4.8 mL, 14.3 mmol, 2.0 eq.) was subjected to Procedure **A** at **-78 °C**. Purification by flash chromatography (SiO<sub>2</sub>, DCM/MeOH, 10/1) afforded (±)-(3*R*,4*S*)-4-methyltetrahydrofuran-3-ol **2d** (105 mg, 14%) as a slight yellow oil.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.03 (d, J = 7.1, 3H, Me), 2.16–2.24 (m, 1H, H<sub>4</sub>), 3.41 (dd, J = 8.5, 4.6, 1H, H<sub>5</sub>), 3.70 (dd, J = 9.8, 2.3, 1H, H<sub>2</sub>), 3.91 (dd, J = 9.8, 4.7, 1H, H<sub>2</sub>), 4.02 (app dt, J = 4.7, 2.3, 1H, H<sub>3</sub>), 4.11 (dd, J = 8.5, 6.5, 1H, H<sub>5</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  16.7 (C<sub>Me</sub>), 42.9 (C<sub>4</sub>), 73.9 (C<sub>5</sub>), 74.5 (C<sub>2</sub>), 78.8 (C<sub>3</sub>).

MS (ESI/HRMS) [M + Na]<sup>+</sup>: calcd. for  $C_5H_{10}O_2Na$ : 125.0573, found 125.0574.

#### (±)-(3R,4S)-4-Ethyltetrahydrofuran-3-ol 2e [387357-51-9]

**Ethyl magnesium bromide** (2.2 mL, 6.47 mmol, 3 M in Et<sub>2</sub>O, 1.5 eq.) was subjected to Procedure **A** at **-20 °C**. Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 1/1) afforded ( $\pm$ )-(3R,4S)-4-ethyltetrahydrofuran-3-ol **2e** as a pale yellow liquid (230 mg, 46%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.96 (t, J = 7.4, 3H, CH<sub>3</sub>), 1.26–1.39 (m, 1H, CH<sub>2</sub>), 1.40–1.54 (m, 1H, CH<sub>2</sub>), 1.94–2.06 (m, 1H, H<sub>4</sub>), 3.45 (dd, J = 8.7, 5.1, 1H, H<sub>5</sub>), 3.71 (dd, J = 9.8, 2.3, 1H, H<sub>2</sub>), 3.85 (dd, J = 9.8, 4.6, 1H, H<sub>2</sub>), 4.06–4.14 (m, 2H, H<sub>3</sub>, H<sub>5</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 12.6 (CH<sub>3</sub>), 24.8 (CH<sub>2</sub>), 50.6 (C<sub>4</sub>), 72.4 (C<sub>5</sub>), 74.8 (C<sub>2</sub>), 77.5 (C<sub>3</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_6H_{12}O_2Na$ : 139.0730, found 139.0728.

# (±)-(3R,4S)-4-Propyltetrahydrofuran-3-ol 2f [2956413-65-1] [1999335-59-9]



*n*-Propyl magnesium chloride (1.6 mL, 3.23 mmol, 2 M in  $Et_2O$ , 1.5 eq.) was subjected to Procedure A at -30 °C. Purification by flash chromatography (SiO<sub>2</sub>, EtOAc, 100%) afforded (±)-(3R,4S)-4-propyltetrahydrofuran-3-ol **2f** (254 mg, 90% yield) as a pale yellow liquid.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.95 (t, J = 7.0, 3H, CH<sub>3</sub>), 1.21–1.52 (m, 4H, 2 CH<sub>2</sub>), 2.10 (m, 1H, H<sub>4</sub>), 3.46 (dd, J = 8.7, 5.3, 1H, H<sub>5</sub>), 3.72 (dd, J = 9.8, 2.4, 1H, H<sub>2</sub>), 3.87 (dd, J = 9.8, 4.6, 1H, H<sub>2</sub>), 4.04–4.18 (m, 2H, H<sub>3</sub>, H<sub>5</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  14.1 (CH<sub>3</sub>), 21.2 (CH<sub>2</sub>), 34.0 (CH<sub>2</sub>), 48.5 (C<sub>4</sub>), 72.5 (C<sub>5</sub>), 74.6 (C<sub>2</sub>), 77.6 (C<sub>3</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_7H_{14}O_2Na$ : 153.0886, found: 153.0888.

# (±)-(3R,4S)-4-Isopropyltetrahydrofuran-3-ol 2g [321903-37-1]



*i*-Propyl magnesium chloride (3.2 mL, 6.47 mmol, 2 M in THF, 1.5 eq.) was subjected to Procedure A at -30 °C. The reagents were introduced at -30 °C, the reaction mixture was allowed to warm up to rt and stirred for 18 h. Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 4/6) afforded ( $\pm$ )-(3*R*,4*S*)-4-isopropyltetrahydrofuran-3-ol as a pale-yellow liquid (221 mg, 39%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.90 (d, J = 6.7, 3H, Me), 1.03 (d, J = 6.7, 3H, Me), 1.58 (dhept, J = 9.0, 6.7, 1H, CH(Me)<sub>2</sub>), 1.81 (app dtd, J = 9.0, 7.4, 3.0, 1H, H<sub>4</sub>), 3.44 (dd, J = 9.0, 7.4, 1H, H<sub>5</sub>), 3.72 (dd, J = 9.9, 3.0, 1H, H<sub>2</sub>), 3.78 (dd, J = 9.9, 5.1, 1H, H<sub>2</sub>), 4.10 (dd, J = 9.0, 7.4, 1H, H<sub>5</sub>), 4.17 (app dt, J = 5.1, 3.0, 1H, H<sub>3</sub>).

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  21.0 (C<sub>Me</sub>), 21.3 (C<sub>Me</sub>), 29.9 (<u>C</u>H(Me)<sub>2</sub>), 56.5 (C<sub>4</sub>), 71.6 (C<sub>5</sub>), 75.6 (C<sub>2</sub>), 76.3 (C<sub>3</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_7H_{15}O_2$ : 131.1067, found 131.1063.  $[M + Na]^+$ : calcd. for  $C_7H_{15}O_2Na$ : 153.0886, found 153.0880.

# (±)-(3R,4S)-4-Cyclohexyltetrahydrofuran-3-ol 2h [1996554-90-5]



**Cyclohexylmagnesium chloride** (6.5 mL, 6.47 mmol, 1 M in 2-MeTHF, 1.5 eq.) was subjected to Procedure **A** at - **30 °C**. Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 7/3) afforded ( $\pm$ )-(3*R*,4*S*)-4-cyclohexyltetrahydrofuran-3-ol **2h** as a slight yellow oil (439 mg, 60%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.92–1.12 (m, 2H, 2 H<sub>cHex</sub>), 1.14–1.30 (m, 4H, H<sub>4</sub>, 3 H<sub>cHex</sub>), 1.55–1.63 (m, 1H, H<sub>cHex</sub>), 1.64–1.78 (m, 3H, 3 H<sub>cHex</sub>), 1.80–1.92 (m, 2H, 2 H<sub>cHex</sub>), 3.45 (dd, J = 9.0, 7.4, 1H, H<sub>5</sub>), 3.71 (dd, J = 9.9, 3.1, 1H, H<sub>2</sub>), 3.77 (dd, J = 9.9, 5.0, 1H, H<sub>2</sub>), 4.09 (dd, J = 9.0, 7.7, 1H, H<sub>5</sub>), 4.20 (app dt, J = 5.0, 3.1, 1H, H<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 26.27 (CH<sub>2cHex</sub>), 26.32 (CH<sub>2cHex</sub>), 26.5 (CH<sub>2cHex</sub>), 31.5 (CH<sub>2cHex</sub>), 31.9 (CH<sub>2cHex</sub>), 39.7 (CH<sub>cHex</sub>), 55.4 (C<sub>4</sub>), 71.4 (C<sub>5</sub>), 75.6 (C<sub>2</sub>), 76.0 (C<sub>3</sub>).

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for C<sub>10</sub>H<sub>18</sub>O<sub>2</sub>Na: 193.1199, found: 193.1200.

# (±)-(3R,4S)-4-Benzyltetrahydrofuran-3-ol 2i [321903-36-0]



Benzyl magnesium chloride (3.23 mL, mmol, 1 M in THF, 1.5 eq.) was subjected to Procedure A at -78 °C. Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 7/3) afforded (±)-(3*R*,4*S*)-4-benzyltetrahydrofuran-3-ol 2i as a colourless oil (200 mg, 52%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.39 (m, 1H, H<sub>4</sub>), 2.58 (dd, J = 13.9, 8.3, 1H, CH<sub>2</sub>Ph), 2.68 (dd, J = 13.9, 7.9, 1H, CH<sub>2</sub>Ph), 3.51 (dd, J = 8.8, 4.6, 1H, H<sub>5</sub>), 3.67 (dd, J = 9.9, 2.6, 1H, H<sub>2</sub>), 3.94 (dd, J = 9.9, 4.9, 1H, H<sub>2</sub>), 3.99 (dd, J = 8.8, 6.5, 1H, H<sub>5</sub>), 4.13 (dt, J = 4.9, 2.6, 1H, H<sub>3</sub>), 7.13–7.20 (m, 3H, 3 H<sub>Ph</sub>), 7.23–7.29 (m, 2H, 2 H<sub>Ph</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 37.7 ( $\underline{C}$ H<sub>2</sub>Ph), 50.1 (C<sub>4</sub>), 72.0 (C<sub>5</sub>), 74.7 (C<sub>2</sub>), 76.8 (C<sub>3</sub>), 126.5 ( $\underline{C}$ H<sub>Ph</sub>), 128.8 (2  $\underline{C}$ H<sub>Ph</sub>), 128.9 (2  $\underline{C}$ H<sub>Ph</sub>), 139.8 ( $\underline{C}$ <sub>QPh</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{11}H_{14}O_2Na$ : 201.0886, found 201.0886.

#### (±)-(3*S*,4*S*)-4-Methoxytetrahydrofuran-3-ol 2k [876026-49-2]



Sodium (830 mg, 36 mmol, 13 eq.) was carefully introduced in a flask containing freshly distilled MeOH (7 mL) at 0 °C under Ar. After vigorous stirring and complete dissolution of solid sodium, 3,6-dioxabicyclo[3.1.0]hexane (243 mg, 2.82 mmol, 1.0 eq.) in MeOH (1M, 2.8 mL) was added dropwise. The mixture obtained was heated at 45 °C for 14 h. Then, the solution was cooled down to 0 °C and acetic acid was added until pH 7. The reaction mixture was concentrated and the solid obtained was taken in EtOAc. The organic phase was washed with NaHCO<sub>3</sub> (15 mL), dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated *in vacuo*. The purification was performed by flash column chromatography on silica gel using EtOAc as eluent affording (±)-(3*S*,4*S*)-4-methoxytetrahydrofuran-3-ol **2k** as a colorless syrup (245 mg, 74%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 3.38 (s, 3H, OMe), 3.69–3.82 (m, 3H, H<sub>2</sub>, H<sub>4</sub>, H<sub>5</sub>), 3.93 (dd, J = 10.0, 3.9, 1H, H<sub>2</sub>), 4.05 (dd, J = 9.7, 4.4, 1H, H<sub>5</sub>), 4.29 (ddd, J = 3.9, 1.8, 1.3, 1H, H<sub>3</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  57.3 (OMe), 71.3 (C<sub>5</sub>), 74.0 (C<sub>2</sub>), 75.1 (C<sub>3</sub>), 87.0 (C<sub>4</sub>).

MS (ESI/HRMS) [M + H] $^+$ : calcd. for  $C_5H_{11}O_3$ : 119.0703, found 119.0703, [M + Na] $^+$ : calcd. for  $C_5H_{10}O_3Na$ : 141.0522, found 141.0522.

# (±)-(3R,4S)-4-(Dimethylamino)tetrahydrofuran-3-ol 2l [30197-51-4]



Dimethylamine (1.41 mL, 9.39 mmol, 2.0 eq., 33% in EtOH) was stirred at 50 °C under Ar and 3,6-dioxabicyclo[3.1.0]hexane (500  $\mu$ L, 4.69 mmol, 1.0 eq.) was added dropwise to the heated solution. The mixture obtained was stirred at 50 °C for 24 h. Then, the solution was cooled down to rt and concentrated *in vacuo*. The residue obtained was filtered on a silica pad and washed with DCM (150 mL). The filtrate was concentrated under reduced pressure affording (±)-(3R,4S)-4-(dimethylamino)tetrahydrofuran-3-ol **2l** as a yellow to orange syrup (610 mg, 99 %).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.29 (s, 6H, 2 Me), 2.74 (ddd, J = 6.8, 6.3, 3.1, 1H, H<sub>4</sub>), 3.64 (dd, J = 9.4, 6.3, 1H, H<sub>5</sub>), 3.70 (dd, J = 10.0, 3.1, 1H, H<sub>2</sub>), 3.94 (dd, J = 10.0, 5.8, 1H, H<sub>2</sub>), 4.03 (dd, J = 9.4, 6.8, 1H, H<sub>5</sub>), 4.32 (app dt, J = 5.8, 3.1, 1H, H<sub>3</sub>).

 $^{13}\text{C NMR}$  (101 MHz, CDCl<sub>3</sub>)  $\delta$  43.8 (2  $C_{\text{Me}}$ ), 70.4 (C<sub>5</sub>), 75.2 (C<sub>3</sub>), 75.3 (C<sub>2</sub>), 75.5 (C<sub>4</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for C<sub>6</sub>H<sub>14</sub>NO<sub>2</sub>: 132.1019, found 132.1018.

# (2R,4r,6S)-2,6-Dimethyltetrahydro-2H-pyran-4-ol 2n [33747-09-0]



2,6-Dimethyl-4H-pyran-4-one (500 mg, 4.03 mmol, 1.0 eq.) was dissolved in abs. ethanol (15 mL) and 20% Pd(OH)<sub>2</sub>/C (141 mg, 0.20 mmol, 5 mol%) was added. The mixture was hydrogenated in a reactor apparatus under H<sub>2</sub> (10 bar) at rt for 72 h. The reaction mixture was filtered through Celite and washed with ethanol (150 mL). The filtrate was concentrated under reduced pressure and the residue was purified by flash column chromatography using gradient pentane/EtOAc (9/1 to 7/3) as eluent which afforded (2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-ol **2n** as a mixture of two diastereoisomers (162 mg, 31%, dr > 82:18).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.07–1.18 (m, 2H, 2 H<sub>3</sub>), 1.23 (d, J = 6.2, 6H, 2 Me), 1.88–1.97 (m, 2H, 2 H<sub>3</sub>), 3.46 (dqd, J = 10.9, 6.2, 1.8, 2H, 2 H<sub>2</sub>), 3.79 (tt, J = 11.1, 4.7, 1H, H<sub>4</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  21.9 (2 C<sub>Me</sub>), 42.9 (2 C<sub>3</sub>), 68.3 (C<sub>4</sub>), 71.6 (2 C<sub>2</sub>).


#### Minor isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.17 (d, J = 6.3, 6H, 2 Me), 1.40–1.48 (m, 2H, 2 H<sub>3</sub>), 1.61–1.67 (m, 2H, 2 H<sub>3</sub>), 3.91 (dqd, J = 12.4, 6.3, 1.9, 2H, 2 H<sub>2</sub>), 4.22 (quin, J = 3.0, 1H, H<sub>4</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  22.1 (2 C<sub>Me</sub>), 40.3 (2 C<sub>3</sub>), 65.1 (C<sub>4</sub>), 67.7 (2 C<sub>2</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_7H_{14}O_2Na$ : 153.0886, found, 153.0887.

#### (+/-)-(3R,4S)-1-Benzyl-4-methylpyrrolidin-3-ol 4g



Sulphuric acid (93%, 227  $\mu$ L, 3.96 mmol, 1.2 eq.) was added dropwise to a solution of 1-Benzyl-2,5-dihydro-1*H*-pyrrole (526 mg, 3.30 mmol, 1.0 eq.) in H<sub>2</sub>O/MeOH (1:4, wv%, 5 mL) at 0 °C. After vigorous stirring for 5 min, *m*CPBA (70%, 1.06 g, 4.30 mmol, 1.3 eq.) was added in one portion and the resulting mixture was allowed to warm up to rt and stirred for 48 h. After complete conversion (monitored by TLC), the mixture was concentrated under reduced pressure. Sodium hydroxide (1M, 15 mL) was added until neutralization of the media (pH 7) and the product was extracted with DCM (3 x 50 mL). The organic phases were combined and washed with water (60 mL) followed by brine (60 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The purification was performed by flash column chromatography on silica gel using DCM/EtOAc/MeOH (7.5:2:0.5) as eluent affording 3-benzyl-6-oxa-3-azabicyclo[3.1.0]hexane (305 mg, 53%) as a brownish syrup.

Methyl magnesium bromide (870  $\mu$ L, 2.61 mmol, 3 M in Et<sub>2</sub>O, 1.5 eq.) was added to a solution of CuI (66mg, 0.35 mmol, 20 mol%) at -78 °C under Ar. After 30 minutes, crude 3-benzyl-6-oxa-3-azabicyclo[3.1.0]hexane (305 mg, 1.74 mmol, 1.0 eq.) was added and the mixture was then allowed to warm up to rt and stirred for 18 h. The mixture was quenched with an aqueous saturated NH<sub>4</sub>Cl solution (15 mL). Then, diluted with water (15 mL) and extracted with diethyl ether (5 x 30 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. Purification by flash column chromatography (SiO<sub>2</sub>, DCM/MeOH, 10:1) afforded the title compound **4g** as a brown to yellow oil (145 mg, 45%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.06 (d, J = 7.3, 3H, Me), 1.94 (dd, J = 9.5, 7.3, 1H, H<sub>5</sub>), 2.17 (app hd, J = 7.3, 2.8, 1H, H<sub>4</sub>), 2.60 (dd, J = 10.4, 5.5, 1H, H<sub>2</sub>), 2.85 (dd, J = 10.4, 2.8, 1H, H<sub>2</sub>), 3.14–3.19 (m, 1H, H<sub>5</sub>), 3.65 (d, J = 13.6, 1H, CH<sub>2</sub>Ph), 3.68 (d, J = 13.6, 1H, CH<sub>2</sub>Ph), 3.84 (app dt, J = 5.5, 2.8, 1H, H<sub>3</sub>), 7.27–7.38 (m, 5H, H<sub>Ph</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  18.1 (C<sub>Me</sub>), 42.8 (C<sub>4</sub>), 60.2 (<u>C</u>H<sub>2</sub>Ph), 60.7 (C<sub>5</sub>), 61.8 (C<sub>2</sub>), 78.6 (C<sub>3</sub>), 127.5 (<u>C</u><sub>HPh</sub>), 128.5 (2 C<sub>HPh</sub>), 129.1 (2 C<sub>HPh</sub>), 137.7 (C<sub>qPh</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{12}H_{18}NO$ : 192.1383, found, 192.1384,  $[M + Na]^+$ : calcd. for  $C_{12}H_{17}NONa$ : 214.1202, found, 214.1203.

# 1-Benzylpiperidin-3-ol 4i [14813-01-5]



Cs<sub>2</sub>CO<sub>3</sub> (3.2 g, 9.9 mmol, 1.0 eq.) and benzyl bromide (1.2 mL, 9.9 mmol, 1.0 eq.) were added to a solution of 3-hydroxypiperidine (1.0 g, 9.9 mmol, 1.0 eq.) in dry acetone (50 mL) and the resulting mixture was stirred at rt for 24 h. After filtration, the filtrate was concentrated under *vacuo*. The purification was performed by flash column chromatography on silica gel using DCM/MeOH (15:1) as eluent affording the title compound **4i** as an orange oil (1.9 g, quant.)

 $^{1}$ H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.44–1.72 and 1.80–1.97 (m, 4H, 2 H<sub>4</sub>, 2 H<sub>5</sub>), 2.27–2.40 (m, 1H, H<sub>6</sub>), 2.48–2.67 (m, 3H, 2 H<sub>2</sub>, H<sub>6</sub>), 3.61 (bs, 2H, C $_{\rm H_2}$ Ph), 3.84–3.92 (m, 1H, H<sub>3</sub>), 7.25–7.36 (m, 5H, H<sub>Ph</sub>).

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  21.6 and 31.7 (C<sub>4</sub> and C<sub>5</sub>), 53.6 (C<sub>6</sub>), 60.2 (C<sub>2</sub>), 63.0 ( $\underline{C}H_2Ph$ ), 66.2 (C<sub>3</sub>), 127.4 (C<sub>Ph</sub>), 128.4 (2 C<sub>Ph</sub>), 129.3 (2 C<sub>Ph</sub>), 137.7 (C<sub>qPh</sub>).

MS (ESI/MS)  $[M + H]^+$ : calcd. for  $C_{12}H_{18}NO$ : 192.1, found 192.1.

# 1-Benzyl-1,2,3,4-tetrahydroquinolin-4-ol 4j [3954-48-1]

In a sealed tube was introduced 2,3-dihydroquinolin-4(1H)-one (106 mg, 0.72 mmol, 1.0 eq.), DIPEA (250  $\mu$ L, 1.44 mmol, 2.0 eq.) and benzyl bromide (100  $\mu$ L, 0.79 mmol, 1.1 eq.) in anhydrous acetonitrile (1 mL). The solution was then stirred at 150 °C for 30 min under microwave irradiation. The mixture was then cool down to rt, diluted with water (10 mL) and extracted with EtOAc (4 x 10 mL). The organic phases were combined and washed with brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated under reduced pressure. The yellow solid obtained as 1-benzyl-4(1H)-quinolinone was used for the next step without further purification.

Crude 1-benzyl-4(1H)-quinolinone (1.0 eq.) was then dissolved in 4 mL of dry MeOH under Ar and NaBH<sub>4</sub> (136 mg, 3.60 mmol, 5.0 eq.) was added portionwise (over 30 min) at 0 °C. After 1 h at 0 °C, the reaction mixture was allowed to warm up to rt and was stirred for 3 h. Then, saturated aqueous NaHCO<sub>3</sub> solution (20 mL) was added and the product was extracted with EtOAc (4 x 15 mL). The organic layers were combined, dried over Na<sub>2</sub>SO<sub>4</sub>, filtered and concentrated in *vacuo*. The residue was purified by flash column chromatography (SiO<sub>2</sub>, pentane/EtOAc, 9/1 to 6/4) to give the title compound **4j** as a brown to pink solid (137 mg, 78% overall yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.94–2.14 (m, 2H, H<sub>3</sub>), 3.29 (dtd, J = 11.6, 4.5, 0.9, 1H, H<sub>2</sub>), 3.59 (td, J = 11.6, 4.5, 1H, H<sub>2</sub>), 4.53 (s, 2H, CH<sub>2</sub>Ph), 4.81 (t, J = 3.7, 1H, H<sub>4</sub>), 6.53–6.60 (m, 1H, H<sub>Ar</sub>), 6.65 (td, J = 7.4, 1.1, 1H, H<sub>Ar</sub>), 7.09 (ddd, J = 8.8, 7.4, 1.7, 1H, H<sub>Ar</sub>), 7.19–7.38 (m, 6H, 5 H<sub>Ph</sub>, H<sub>Ar</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 29.9 (C<sub>3</sub>), 44.5 (C<sub>2</sub>), 55.2 ( $\underline{C}$ H<sub>2</sub>Ph), 66.2 (C<sub>4</sub>), 111.7 (C<sub>Ar</sub>), 116.1 (C<sub>Ar</sub>), 123.5 (C<sub>qAr</sub>), 126.7 (2 C<sub>Ph</sub>), 127.1 (C<sub>Ph</sub>), 128.8 (2 C<sub>Ph</sub>), 129.8 (C<sub>Ar</sub>), 129.9 (C<sub>Ar</sub>), 138.6 (C<sub>qAr</sub>), 145.2 (C<sub>qPh</sub>).

MS (ESI/HR)  $[M + Na]^+$ : calcd. for  $C_{16}H_{17}NONa$ : 262.1202, found 262.1203.  $[M + H]^+$ : calcd. for  $C_{16}H_{18}NO$ : 240.1383, found 240.1382.

# BH C-C coupling with secondary O- and N-heterocyclic alcohols

# 1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone 3a [2956413-69-5]



Tetrahydrofuran-3-ol (22 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/Et<sub>2</sub>O, 8/2) afforded the title compound **3a** (47 mg, 71%) as a yellow solid.


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.50–1.64 (m, 1H, H<sub>4</sub>'), 2.08–2.12 (m, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.20–2.31 (m, 1H, H<sub>4</sub>'), 2.70–2.91 (m, 3H, 2 H<sub>2</sub>, H<sub>3</sub>'), 3.40–3.49 (m, 1H, H<sub>2</sub>'), 3.78 (app dt, J = 8.4, 7.4, 1H, H<sub>5</sub>'), 3.86 (app td, J = 8.4, 4.9, 1H, H<sub>5</sub>'), 4.04–4.12 (m, 1H, H<sub>2</sub>').

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.1 (2  $\underline{\text{CH}}_3$ ), 16.8 ( $\underline{\text{C}}_{\text{H}_3}$ ), 17.3 (2  $\underline{\text{CH}}_3$ ), 32.5 (C<sub>4</sub>′), 34.1 (C<sub>3</sub>′), 49.7 (C<sub>2</sub>), 67.8 (C<sub>5</sub>′), 73.3 (C<sub>2</sub>′), 127.3 (2  $\underline{\text{C}}_{\text{QAr}}$ ), 133.3 (2  $\underline{\text{C}}_{\text{QAr}}$ ), 135.7 (C<sub>QAr</sub>), 140.3 (C<sub>QAr</sub>), 210.9 (C<sub>1</sub>).

MS (ESI/HRMS) [M + Na]<sup>+</sup>: calcd. for  $C_{17}H_{24}O_2Na$ : 283.1669, found 283.1664, [M + H]<sup>+</sup>: calcd. for  $C_{17}H_{25}O_2$ : 261.1849, found 261.1846.

m.p. = 72-79 °C

# 2-(5-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3b [2956413-71-9/2956413-70-8]



5-Methyltetrahydrofuran-3-ol (26 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **[Cp\*IrCl<sub>2</sub>]<sub>2</sub>**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, Pentane/EtOAc, 95/5 to 80/20) afforded the title compound **3b** (44 mg, 64%, dr 61:39 - measured after purification) as a yellow solid.

### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.12 (ddd, J = 12.3, 9.4, 8.3, 1H, H<sub>4′</sub>), 1.27 (d, J = 5.9, 3H, Me), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.37 (ddd, J = 12.3, 6.9, 5.8, 1H, H<sub>4′</sub>), 2.71–2.93 (m, 3H, 2 H<sub>2</sub>, H<sub>3′</sub>), 3.57 (dd, J = 8.7, 6.2, 1H, H<sub>2′</sub>), 3.99 (dqd, J = 9.4, 5.9, 5.8, 1H, H<sub>5′</sub>), 4.04–4.12 (m, 1H, H<sub>2′</sub>).

<sup>13</sup>C NMR (101 M, CDCl<sub>3</sub>) δ 16.1 (2  $\underline{\text{CH}}_3$ ), 16.8 ( $\underline{\text{CH}}_3$ ), 17.3 (2  $\underline{\text{CH}}_3$ ), 21.1 (C<sub>Me</sub>), 35.0 (C<sub>3</sub>'), 40.6 (C<sub>4</sub>'), 50.4 (C<sub>2</sub>), 72.9 (C<sub>2</sub>'), 75.7 (C<sub>5</sub>'), 127.3 (2 C<sub>qAr</sub>), 133.3 (2 C<sub>qAr</sub>), 135.7 (C<sub>qAr</sub>), 140.3 (C<sub>qAr</sub>), 211.0 (C<sub>1</sub>).

#### Minor isomer:


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.25 (d, J = 6.1, 3H, Me), 1.73 (ddd, J = 12.6, 7.0, 5.6, 1H, H<sub>4</sub>'), 1.84 (ddd, J = 12.6, 8.3, 6.9, 1H, H<sub>4</sub>'), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.71–2.93 (m, 3H, 2 H<sub>2</sub>, H<sub>3</sub>'), 3.40 (dd, J = 8.8, 6.6, 1H, H<sub>2</sub>'), 4.04–4.12 (m, 3H, H<sub>5</sub>'), 4.23 (dd, J = 8.8, 6.8, 1H, H<sub>2</sub>').

<sup>13</sup>C NMR (101 M, CDCl<sub>3</sub>) δ 16.1 (2  $\underline{\text{CH}}_3$ ), 16.8 ( $\underline{\text{CH}}_3$ ), 17.3 (2  $\underline{\text{CH}}_3$ ), 21.4 (C<sub>Me</sub>), 34.0 (C<sub>3</sub>′), 39.4 (C<sub>4</sub>′), 49.7 (C<sub>2</sub>), 73.3 (C<sub>2</sub>′), 74.6 (C<sub>5</sub>′), 127.3 (2 C<sub>QAr</sub>), 133.3 (2 C<sub>QAr</sub>), 135.7 (C<sub>QAr</sub>), 140.3 (C<sub>QAr</sub>), 210.9 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{18}H_{26}O_2Na$ : 297.1825, found 297.1823,  $[M + H]^+$ : calcd. for  $C_{18}H_{27}O_2$ : 275.2006, found 275.2008.

m.p. = 95-98 °C

# 2-(2-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3c



(2*S*,3*S*)-2-Methyltetrahydrofuran-3-ol (11 mg, 0.11 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ru-MACHO**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, gradient pentane/EtOAc, 95/5 to 9/1) afforded the title compound **3c** as a yellow solid, (9 mg, 30%, dr 99:1 - *measured after purification*).

#### Major isomer:


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.09 (d, J = 6.5, 3H, Me), 1.66–1.78 (m, 1H, H<sub>4′</sub>), 2.11 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.25–2.41 (m, 1H, H<sub>4′</sub>), 2.63–2.82 (m, 3H, 2 H<sub>2</sub>, H<sub>3′</sub>), 3.75 (app q, J = 8.1, 1H, H<sub>5′</sub>), 3.94 (app td, J = 8.1, 4.4, 1H, H<sub>5′</sub>), 4.12-4.21 (m, 1H, H<sub>2′</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.1 (2  $\underline{C}$ H<sub>3</sub>), 16.7 ( $\underline{C}$ H<sub>3</sub>), 16.8 ( $\underline{C}$ H<sub>3</sub>), 17.3 (2  $\underline{C}$ H<sub>3</sub>), 31.9 (C<sub>4</sub>′), 36.7 (C<sub>3</sub>′),45.7 (C<sub>2</sub>), 66.4 (C<sub>5</sub>′), 76.4 (C<sub>2</sub>′), 127.4 (2 C<sub>QAr</sub>), 133.3 (2 C<sub>QAr</sub>), 135.7 (C<sub>QAr</sub>), 140.6 (C<sub>QAr</sub>), 211.0 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{18}H_{26}O_2Na$ : 297.1825, found 297.1829,  $[M + H]^+$ : calcd. for  $C_{18}H_{27}O_2$ : 275.2006, found 275.2010.

 $m.p. = 67-69 \, ^{\circ}C$ 

# 2-(4-Methyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3d [2956413-73-1/2956413-72-0]



(3R,4S)-4-Methyltetrahydrofuran-3-ol (20 mg, 0.20 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ru-MACHO**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 9/1) afforded the title compound **3d** as a yellow solid, (34 mg, 62%, dr 95:5 - *measured after purification*).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.94 (d, J = 7.1, 3H, Me), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.41–2.51 (m, 1H, H<sub>4</sub>′), 2.59–2.72 (m, 1H, H<sub>2</sub>), 2.75–2.88 (m, 2H, H<sub>2</sub>′), 3.44 (dd, J = 8.3, 5.1, 1H, H<sub>5</sub>′), 3.56 (dd, J = 8.5, 7.0, 1H, H<sub>2</sub>′), 3.95 (dd, J = 8.3, 6.4, 1H, H<sub>5</sub>′), 4.16 (dd, J = 8.5, 7.2, 1H, H<sub>2</sub>′).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \, \delta \, 13.5 \, (C_{\text{Me}}), \, 16.1 \, (2 \, \underline{\text{C}}\text{H}_3), \, 16.8 \, (\underline{\text{C}}\text{H}_3), \, 17.3 \, (2 \, \underline{\text{C}}\text{H}_3), \, 35.7 \, (C_{4'}), \, 37.2 \, (C_{3'}), \, 44.2 \, (C_2), \, 72.6 \, (C_{2'}), \, 74.8 \, (C_{5'}), \, 127.3 \, (2 \, C_{\text{qAr}}), \, 133.3 \, (2 \, C_{\text{qAr}}), \, 135.7 \, (C_{\text{qAr}}), \, 140.5 \, (C_{\text{qAr}}), \, 211.0 \, (C_1).$ 

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{18}H_{26}O_2Na$ : 275.2006, found 275.2001,  $[M + H]^+$ : calcd. for  $C_{18}H_{27}O_2$ : 297.1825, found 297.1819.

m.p. = 91-93 °C

# 2-(4-Ethyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3e [2956413-75-3] [2956413-74-2]

(3*R*,4*S*)-4-Ethyltetrahydrofuran-3-ol (29 mg, 0.25 mmol, 1.0 eq) was subjected to Procedure **B** using Ir-1. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 95/5) afforded the title compound **3e** as a yellow solid, (42 mg, 58%, dr 81:19 - *measured after purification*).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.92 (t, J = 7.4, 3H, H<sub>T</sub>), 1.20–1.48 (m, 2H, H<sub> $\theta$ </sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.22-2.26 (m, 1H, H<sub> $\theta$ </sub>), 2.65 (dd, J = 19.2, 10.8, 1H, H<sub>2</sub>), 2.72–2.89 (m, 2H, H<sub>3</sub>, H<sub>2</sub>), 3.44 (app t, J = 8.1, 1H, H<sub> $\theta$ </sub>), 3.67 (dd, J = 8.6, 4.6, 1H, H<sub> $\theta$ </sub>), 3.93 (dd, J = 8.1, 7.2, 1H, H<sub> $\theta$ </sub>), 4.10 (m, 1H, H<sub> $\theta$ </sub>).

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  13.0 (C<sub>7</sub>'), 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.3 (2 CH<sub>3</sub>), 20.8 (C<sub>6</sub>'), 36.4 (C<sub>3</sub>'), 43.6 (C<sub>4</sub>'), 43.7 (C<sub>2</sub>), 72.0 (C<sub>5</sub>'), 73.5 (C<sub>2</sub>'), 127.3 (2 C<sub>qAr</sub>), 133.3 (2 C<sub>qAr</sub>), 135.7 (C<sub>qAr</sub>), 140.6 (C<sub>qAr</sub>), 211.1 (C<sub>1</sub>).

### Minor isomer:


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.93 (t, J = 7.5, 3H, H<sub>7</sub>), 1.20–1.48 (m, 1H, H<sub>6</sub>), 1.54–1.63 (m, 1H, H<sub>6</sub>), 1.69–1.80 (m, 1H, H<sub>4</sub>), 2.09 (s, 6H, 3 CH<sub>3</sub>), 2.19 (s, 6H, 3 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.37–2.45 (m, 1H, H<sub>3</sub>), 2.59–2.73 (m, 1H, H<sub>2</sub>), 2.96 (dd, J = 19.0, 3.9, 1H, H<sub>2</sub>), 3.41 (dd, J = 8.6, 7.3, 1H, H<sub>5</sub>), 3.52 (dd, J = 8.9, 6.4, 1H, H<sub>2</sub>), 3.98 (dd, J = 8.6, 7.2, 1H, H<sub>5</sub>), 4.23 (dd, J = 8.9, 7.3, 1H, H<sub>2</sub>).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 12.8 \ (\text{C}_{7'}), \ 16.1 \ (2 \ \text{CH}_3), \ 16.8 \ (\text{CH}_3), \ 17.3 \ (2 \ \text{CH}_3), \ 25.8 \ (\text{C}_{6'}), \ 40.2 \ (\text{C}_{3'}), \ 47.1 \ (\text{C}_{4'}), \ 50.0 \ (\text{C}_2), \ 73.0 \ (\text{C}_{5'}), \ 73.9 \ (\text{C}_{2}), \ 127.3 \ (2 \ \text{C}_{\text{QAr}}), \ 135.7 \ (\text{C}_{\text{QAr}}), \ 140.6 \ (\text{C}_{\text{QAr}}), \ 211.1 \ (\text{C}_1).$ 

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{19}H_{28}O_2Na$ : 311.1982, found 311.1985,  $[M + H]^+$ : calcd. for  $C_{19}H_{29}O_2$ : 289.2162, found 289.2166.

m.p. = 67 °C

### 1-(2,3,4,5,6-Pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethenone 3f [2956413-75-3/2956413-74-2]



(3R,4S)-4-Propyltetrahydrofuran-3-ol (33 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 95:5 to 80:20) afforded the title compound **3f** as a brown oil (53 mg, 70%, dr 50:50 - *measured after purification*). The diastereoisomers were assigned when it was possible due to the overlap signals (dia 2 = major diastereoisomer using Ru-MACHO).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  0.91 (m, 6H, 2 CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 1 and 2), 1.18–1.41 (m, 7H, 2 CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 1 and 2), 1.53–1.81 (m, 2H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, H<sub>4</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.11 (s, 6H, 2 CH<sub>3</sub>), 2.19 (2 s, 12H, 4 CH<sub>3</sub>), 2.24 (2 s, 6H, 2 CH<sub>3</sub>), 2.28–2.46 (m, 2H, H<sub>3</sub>', H<sub>4</sub>'), 2.66 (m, 2H, 2 H<sub>2</sub>), 2.75–2.87 (m, 2H, H<sub>3</sub>', H<sub>2</sub>), 2.97 (dd, J = 18.9, 3.8, 1H, H<sub>2</sub>), 3.35–3.47 (m, 2H, 2 H<sub>5</sub>'), 3.52 (dd, J = 8.8, 6.5, 1H, H<sub>2</sub>', dia 1), 3.67 (dd, J = 8.7, 4.4, 1H, H<sub>2</sub>', dia 2), 3.95 (m, 2H, 2 H<sub>5</sub>'), 4.11 (ddd, J = 8.7, 6.0, 1.0, 1H, H<sub>2</sub>', dia 2), 4.24 (dd, J = 8.8, 7.3, 1H, H<sub>2</sub>', dia 1).

 $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  14.38 and 14.40 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 1 and 2), 16.1 (4 CH<sub>3</sub>), 16.8 (2 CH<sub>3</sub>), 17.22 and 17. 24 (4 CH<sub>3</sub>), 21.66 and 21.75 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 1 and 2), 30.2 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 1), 35.1 (CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, dia 2), 36.5 and 40.5 (C<sub>3</sub>'), 41.6 (C<sub>4</sub>'), 43.8 (C<sub>2</sub>, dia 2), 45.1 (C<sub>4</sub>'), 49.8 (C<sub>2</sub>, dia 1), 72.3; 73.3; 73.5; 73.8 (2 C<sub>2</sub>', 2 C<sub>5</sub>'), 127.28 and 127.33 (4 C<sub>qAr</sub>), 133.26 and 133.31 (4 C<sub>qAr</sub>), 135.66 and 135.69 (2 C<sub>qAr</sub>), 140.3 (C<sub>qAr</sub>), 140.6 (C<sub>qAr</sub>), 211.1 (2 C<sub>1</sub>).

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{20}H_{30}O_2Na$ : 325.2138, found 325.2138,  $[M + H]^+$ : calcd. for  $C_{20}H_{31}O_2$ : 303.2319, found 303.2321.

# 2-(5-2-(4-Isopropyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3g

(3*R*,4*S*)-4-Isopropyltetrahydrofuran-3-ol (33 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 95/5) afforded the title compound **3g** as a brown oil (46 mg, 61%, dr 70:30 - *measured after purification*).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.87 (d, J = 6.5, 3H, Me), 0.96 (d, J = 6.5, 3H, Me), 1.48 (dhept, J = 10.7, 6.5, 1H, CH(Me)<sub>2</sub>), 2.01 (app tdd, J = 10.7, 8.3, 6.3, 1H, H<sub>4</sub>′), 2.12 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.63-2.86 (m, 3H, 2 H<sub>2</sub>, H<sub>3</sub>′), 3.37 (dd, J = 10.7, 8.1, 1H, H<sub>5</sub>′), 3.87–4.03 (m, 3H, 2 H<sub>2</sub>′, H<sub>5</sub>′).

<sup>13</sup>C NMR (101 M, CDCl<sub>3</sub>)  $\delta$  16.0 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 21.8 (C<sub>Me</sub>), 22.1 (C<sub>Me</sub>), 27.4 (CH(Me)<sub>2</sub>), 35.5 (C<sub>3</sub>'), 42.7 (C<sub>2</sub>), 50.3 (C<sub>4</sub>'), 70.9 (C<sub>5</sub>'), 74.4 (C<sub>2</sub>'), 127.3 (2 C<sub>QAr</sub>), 133.3 (2 C<sub>QAr</sub>), 135.6 (C<sub>QAr</sub>), 140.5 (C<sub>QAr</sub>), 211.2 (C<sub>1</sub>).

#### Minor isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.90 (d, J = 6.6, 3H, Me), 0.97 (d, J = 6.6, 3H, Me), 1.55–1 .63 (m, 1H, H<sub>4</sub>'), 1.63–1.74 (m, 1H, C<u>H</u>(Me)<sub>2</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.50–2.60 (m, 1H, H<sub>3</sub>'), 2.62–2.80 (m, 1H, H<sub>2</sub>), 2.96 (dd, J = 19.2, 3.1, 1H, H<sub>2</sub>), 3.46 (dd, J = 8.9, 7.4, 1H, H<sub>5</sub>'), 3.59 (dd, J = 9.1, 5.2, 1H, H<sub>2</sub>'), 3.87–4.03 (m, 1H, H<sub>5</sub>'), 4.17 (dd, J = 9.1, 7.3, 1H, H<sub>2</sub>').

 $^{13}\text{C NMR (101 M, CDCl}_3) \ \delta \ 16.0 \ (2 \ \underline{\text{CH}}_3), \ 16.8 \ (\underline{\text{CH}}_3), \ 17.2 \ (2 \ \underline{\text{CH}}_3), \ 20.6 \ (\text{C}_{\text{Me}}), \ 21.5 \ (\text{C}_{\text{Me}}), \ 31.1 \ (\underline{\text{CH}}(\text{Me})_2), \ 37.9 \ (\text{C}_3'), \ 51.5 \ (\text{C}_2), \ 52.2 \ (\text{C}_{4'}), \ 71.6 \ (\text{C}_5'), \ 74.5 \ (\text{C}_2'), \ 127.3 \ (2 \ \text{C}_{\text{QAr}}), \ 133.3 \ (2 \ \text{C}_{\text{QAr}}), \ 135.6 \ (\text{C}_{\text{QAr}}), \ 140.2 \ (\text{C}_{\text{QAr}}), \ 211.2 \ (\text{C}_1).$ 

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for:  $C_{20}H_{30}O_2Na$ : 325.2138, found 325.2138, [M + H] $^+$ : calcd. For  $C_{20}H_{29}O_2$ : 303.2319, found 303.2320.

#### 2-(4-Cyclohexyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3h

(3R,4S)-4-Cyclohexyltetrahydrofuran-3-ol (43 mg, 0.25 mmol, 1.0 eq.), pentamethylacetophenone was subjected to Procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/Et<sub>2</sub>O, 90:10) afforded the title compound **3h** as a pinkish solid (39 mg, 45%, dr 65:35 - *measured after purification*).

### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.93–1.81 (m, 11H, H<sub>6</sub>′, 10 H<sub>cHex</sub>), 2.00–2.08 (m, 1H, H<sub>4</sub>′), 2.11 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.62–2.78 (m, 2H, 2 H<sub>2</sub>), 2.82 (m, 1H, H<sub>3</sub>′), 3.37 (dd, J = 10.7, 8.0, 1H, H<sub>5</sub>′), 3.89 (dd, J = 8.8, 1.3, 1H, H<sub>2</sub>′), 3.92–3.99 (m, 2H, H<sub>2</sub>′, H<sub>5</sub>′).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.1 (2  $\underline{\text{C}}$ H<sub>3</sub>), 16.8 ( $\underline{\text{C}}$ H<sub>3</sub>), 17.1 (2  $\underline{\text{C}}$ H<sub>3</sub>), 26.1 ( $\underline{\text{C}}$ cHex), 26.2 ( $\underline{\text{C}}$ cHex), 26.5 ( $\underline{\text{C}}$ cHex), 32.3 ( $\underline{\text{C}}$ cHex), 34.8 ( $\underline{\text{C}}$ 3'), 37.1 ( $\underline{\text{C}}$ 6'), 42.9 ( $\underline{\text{C}}$ 2), 48.6 ( $\underline{\text{C}}$ 4'), 70.7 ( $\underline{\text{C}}$ 5'), 74.3 ( $\underline{\text{C}}$ 2'), 127.4 (2  $\underline{\text{C}}$ qAr), 133.3 (2  $\underline{\text{C}}$ qAr), 135.7 ( $\underline{\text{C}}$ qAr), 140.6 ( $\underline{\text{C}}$ qAr), 211.2 ( $\underline{\text{C}}$ 1).

#### Minor isomer:


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.90–1.83 (m, 12H, H<sub>4</sub>′, H<sub>6</sub>′, 10 H<sub>cHex</sub>), 2.09 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.52–2.62 (m, 1H, H<sub>3</sub>′), 2.62–2.78 (m, 1H, H<sub>2</sub>), 2.93 (dd, J = 19.1, 3.0, 1H, H<sub>2</sub>), 3.45 (dd, J = 8.8, 7.7, 1H, H<sub>5</sub>′), 3.58 (dd, J = 9.1, 5.0, 1H, H<sub>2</sub>′), 3.91–3.98 (m, 1H, H<sub>5</sub>′), 4.12 (dd, J = 9.1, 7.3, 1H, H<sub>2</sub>′).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{C}}_{\text{H}3}), \ 16.8 \ (\underline{\text{C}}_{\text{H}3}), \ 17.2 \ (2 \ \underline{\text{C}}_{\text{H}3}), \ 26.4 \ (C_{\text{cHex}}), \ 26.5 \ (C_{\text{cHex}}), \ 26.6 \ (C_{\text{cHex}}), \ 31.3 \ (C_{\text{cHex}}), \ 32.1 \ (C_{\text{cHex}}), \ 37.5 \ (C_{3'}), \ 41.2 \ (C_{6'}), \ 51.2 \ (C_{4'}), \ 51.7 \ (C_{2}), \ 71.7 \ (C_{5'}), \ 74.4 \ (C_{2'}), \ 127.3 \ (2 \ C_{qAr}), \ 133.3 \ (2 \ C_{qAr}), \ 135.7 \ (C_{qAr}), \ 140.3 \ (C_{qAr}), \ 211.3 \ (C_{1}).$ 

MS (ESI/HR)  $[M + H]^+$ : calcd. for  $C_{23}H_{35}O_2$ : 343.2632, found 343.2631,  $[M + Na]^+$ : calcd. for  $C_{23}H_{34}O_2Na$ : 365.2451, found 365.2449.

m.p. = 119-122 °C

#### 2-(4-Benzyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3i



(3R,4S)-4-Benzyltetrahydrofuran-3-ol (45 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 92/8) afforded the title compound **3i** as a yellow solid (69 mg, 79%, dr 66:34 - *measured after purification*).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.09 (s, 6H, 2 CH<sub>3</sub>), 2.20 (s, 6H, 2 CH<sub>3</sub>), 2.25 (s, 3H, CH<sub>3</sub>), 2.47–2.84 (m, 4H, C $\underline{\text{H}}_{2}$ Ph, H<sub>2</sub>, H<sub>4</sub>'), 2.84–2.98 (m, 2H, H<sub>3</sub>', H<sub>2</sub>), 3.47–3.57 (m, 1H, H<sub>5</sub>'), 3.72 (dd, J = 8.7, 5.4, 1H, H<sub>2</sub>'), 3.78–3.83 (m, 1H, H<sub>5</sub>'), 4.15–4.20 (m, 1H, H<sub>2</sub>'), 7.13–7.23 (m, 3H, H<sub>Ph</sub>), 7.24–7.32 (m, 2H, H<sub>Ph</sub>).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.1 \ (2 \ \text{CH}_3), \ 16.8 \ (\text{CH}_3), \ 17.3 \ (2 \ \text{CH}_3), \ 33.9 \ (\underline{\text{C}}_{\text{H}_2}\text{Ph}), \ 36.7 \ (C_{3'}), \ 43.0 \ (C_{4'}), \ 44.0 \ (C_2), \ 71.9 \ (C_{5'}), \ 73.3 \ (C_{2'}), \ 126.3 \ (C_{\text{HAr}}), \ 128.7 \ (2 \ \text{C}_{\text{HAr}}), \ 128.8 \ (2 \ \text{C}_{\text{HAr}}), \ 133.4 \ (2 \ \text{C}_{\text{QAr}}), \ 135.8 \ (C_{\text{QAr}}), \ 140.2 \ (C_{\text{QAr}}), \ 140.4 \ (C_{\text{QAr}}), \ 210.8 \ (C_{1}).$ 

#### Minor isomer:


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.99 (s, 6H, 2 CH<sub>3</sub>), 2.11–2.18 (masked m, 1H, H<sub>4</sub>'), 2.16 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.47–2.84 (m, 5H, H<sub>2</sub>, H<sub>3</sub>', CH<sub>2</sub>Ph), 3.47–3.57 (m, 2H, H<sub>2</sub>', H<sub>5</sub>'), 3.90 (dd, J = 8.8, 7.2, 1H, H<sub>5</sub>'), 4.32 (dd, J = 9.0, 7.2, 1H, H<sub>2</sub>'), 7.13–7.23 (m, 3H, H<sub>Ar</sub>), 7.24–7.32 (m, 2H, H<sub>Ar</sub>).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.0 \ (2 \ \text{CH}_3), \ 16.8 \ (\text{CH}_3), \ 17.2 \ (2 \ \text{CH}_3), \ 39.2 \ (\underline{\text{C}}_{\text{H}_2}\text{Ph}), \ 40.0 \ (\text{C}_{3'}), \ 46.8 \ (\text{C}_{4'}), \ 50.1 \ (\text{C}_2), \ 73.1 \ (\text{C}_{5'}), \ 74.2 \ (\text{C}_{2'}), \ 126.4 \ (\text{C}_{\text{HAr}}), \ 127.3 \ (2 \ \text{C}_{\text{HAr}}), \ 128.8 \ (2 \ \text{C}_{\text{HAr}}), \ 133.2 \ (2 \ \text{C}_{\text{QAr}}), \ 135.6 \ (\text{C}_{\text{QAr}}), \ 140.1 \ (\text{C}_{\text{QAr}}), \ 140.3 \ (\text{C}_{\text{QAr}}), \ 211.0 \ (\text{C}_1).$ 

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{24}H_{30}O_2Na$ : 373.2138, found 373.2137.  $[M + H]^+$ : calcd. for  $C_{24}H_{31}O_2$ : 351.2319, found 351.2317.

m.p. = 94-98 °C

# 2-((3R,6S)-6-(Tert-butoxy)hexahydrofuro[3,2-b]furan-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3j<sup>5</sup>



(3*R*,6*S*)-6-(*Tert*-Butoxy)hexahydrofuro[3,2-*b*]furan-3-ol (91 mg, 0.45 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 95:5 to 90:10) afforded the title compound **3j** as a yellow solid (79 mg, 47%, dr >99:1).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.22 (s, 9H, <sup>t</sup>Bu-CH<sub>3</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.64–2.87 (m, 2H, H<sub>2</sub>, H<sub>3</sub>'), 3.09 (dd, J = 21.0, 8.7, 1H, H<sub>2</sub>), 3.37 (dd, J = 10.3, 7.9, 1H, H<sub>2</sub>'), 3.61 (dd, J = 9.4, 3.5, 1H, H<sub>5</sub>'), 3.86 (dd, J = 9.4, 5.0, 1H, H<sub>5</sub>'), 4.07 (ddd, J = 5.0, 3.5, 1.6, 1H, H<sub>6</sub>'), 4.15 (app t, J = 7.9, 1H, H<sub>2</sub>'), 4.43 (dd, J = 4.0, 1.6, 1H, H<sub>6</sub>'a), 4.74 (app t, J = 4.0, 1H, H<sub>3</sub>'a).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{C}}\text{H}_3), \ 16.8 \ (2 \ \underline{\text{C}}\text{H}_3), \ 17.3 \ (\underline{\text{C}}\text{H}_3), \ 28.4 \ (3 \ \underline{\text{C}}\text{H}_3), \ 40.0 \ (C_{3'}), \ 42.4 \ (C_2), \ 71.6 \ (C_{2'}), \ 74.5 \ (\underline{\text{C}}(\text{CH}_3)_3), \ 74.9 \ (C_{5'}), \ 77.3 \ (C_{6'}), \ 83.3 \ (C_{3'a}), \ 89.7 \ (C_{6'a}), \ 127.4 \ (2 \ C_{qAr}), \ 133.2 \ (2 \ C_{qAr}), \ 135.6 \ (C_{qAr}), \ 140.4 \ (C_{qAr}), \ 210.7 \ (C_1).$ 

 $[\alpha]_{21}^D$  = + 72.7° (c 0.47 CHCl<sub>3</sub>)

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{23}H_{34}O_4Na$ : 397.2349, found 397.2330,  $[M + H]^+$ : calcd. for  $C_{23}H_{35}O_4$ : 375.2530, found 375.2512.

m.p. = 118-121 °C

# $(\pm)$ -2-((3R,4R)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3k [2956413-76-4]

(3*S*,4*S*)-4-Methoxytetrahydrofuran-3-ol **2k** (32 mg, 0.27 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 9/1) afforded the title compound **3k** as a yellowish solid, (23 mg, 29%, dr >99:1, determined by  ${}^{1}H$  NMR). After recrystallization from Et<sub>2</sub>O/pentane at rt colourless needle crystals suitable for X-ray crystallography were obtained.

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.12 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.72 (dd, J = 19.0, 5.7, 1H, H<sub>2</sub>), 2.80 (m, 1H, H<sub>3</sub>'), 3.10 (dd, J = 19.0, 7.7, 1H, H<sub>2</sub>), 3.30 (s, 3H, OCH<sub>3</sub>), 3.52 (dd, J = 9.7, 7.9, 1H, H<sub>2</sub>), 3.86 (dd, J = 10.0, 3.7, 1H, H<sub>5</sub>'), 3.97 (dd, J = 10.0, 1.4, 1H, H<sub>5</sub>'), 4.05–4.12 (m, 2H, H<sub>2</sub>').

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \, \delta \, 16.1 \, (2 \, \underline{\text{CH}}_3), \, 16.8 \, (\underline{\text{C}}_{\text{H}_3}), \, 17.1 \, (2 \, \underline{\text{C}}_{\text{H}_3}), \, 38.8 \, (C_{3'}), \, 42.1 \, (C_2), \, 57.0 \, (C_{\text{Me}}), \, 71.4 \, (C_{2'}), \, 71.7 \, (C_{5'}), \, 81.2 \, (C_{4'}), \, 127.4 \, (2 \, C_{\text{qAr}}), \, 133.2 \, (2 \, C_{\text{qAr}}), \, 135.6 \, (C_{\text{qAr}}), \, 140.5 \, (C_{\text{qAr}}), \, 211.0 \, (C_1).$ 

IR (ATR) v 648, 713, 754, 838, 898, 937, 966, 1043, 1081, 1100, 1114, 1167, 1190, 1221, 1310, 1374, 1398, 1450, 1697, 1732, 2857, 2887, 2920.

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{18}H_{26}O_3Na$ : 313.1774, found 313.1772,  $[M + H]^+$ : calcd. for  $C_{18}H_{27}O_3$ : 291.1955, found 291.1954.

#### 2-(4-(Dimethylamino)tetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3l

(3R,4S)-4-(Dimethylamino)tetrahydrofuran-3-ol (33 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, gradient pentane/EtOAc, 9/1 to 1/1) afforded the title compound **3l** as a yellow solid (22 mg, 29%, dr >99:1 determined by <sup>1</sup>H NMR).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 2.11 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 12H, 2 CH<sub>3</sub>, 2 Me), 2.22 (s, 3H, CH<sub>3</sub>), 2.70 (dd,  $J = 19.7, 10.3, 1H, H_2$ ), 2.75-2.82 (m, 1H, H<sub>4</sub>'), 2.86–2.96 (m, 1H, H<sub>3</sub>'), 3.16 (app dt,  $J = 19.7, 1.4, 1H, H_2$ ), 3.53 (app t,  $J = 8.6, 1H, H_5$ '), 3.82–3.92 (m, 2H, H<sub>2</sub>', H<sub>5</sub>'), 4.04 (ddd,  $J = 8.9, 4.9, 1.4, 1H, H_2$ ).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{CH}}_3), \ 16.8 \ (\underline{\text{CH}}_3), \ 17.2 \ (2 \ \underline{\text{CH}}_3), \ 36.1 \ (C_{3'}), \ 42.9 \ (C_2), \ 45.0 \ (2 \ C_{\text{Me}}), \ 68.6 \ (C_{4'}), \ 69.8 \ (C_{5'}), \ 73.7 \ (C_{2'}), \ 127.2 \ (2 \ C_{\text{qAr}}), \ 133.1 \ (2 \ C_{\text{qAr}}), \ 135.5 \ (C_{\text{qAr}}), \ 140.5 \ (C_{\text{qAr}}), \ 211.7 \ (C_1).$ 

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{19}H_{30}NO_2$ : 304.2271, found 304.2275.

m.p. = 66-67  $^{\circ}$ C

# 1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydro-2H-pyran-4-yl)ethanone 3m



#### 3m

Tetrahydro-2*H*-pyran-4-ol (27 mg, 0.26 mmol, 1.0 eq) was subjected to procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, gradient 95/5 to 8/2) afforded the title compound **3m** as a yellow solid (16 mg, 22%).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.29–1.41 (m, 2H, H<sub>3'</sub>), 1.78 (app ddt, J = 12.9, 4.1, 2.1, 2H, H<sub>3'</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.20–2.36 (m, 1H, H<sub>4'</sub>), 2.62 (d, J = 6.5, 2H, H<sub>2</sub>), 3.49 (ddd, J = 11.8, 11.5, 2.1, 2H, H<sub>2'</sub>), 3.96 (app ddt, J = 11.5, 4.1, 1.6, 2H, H<sub>2</sub>).

<sup>13</sup>C NMR (101 M, CDCl<sub>3</sub>)  $\delta$  16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.1 (2 CH<sub>3</sub>), 30.0 (C<sub>4</sub>′), 33.1 (C<sub>3</sub>′), 52.5 (C<sub>2</sub>), 68.0 (C<sub>2</sub>′), 127.3 (2 C<sub>qAr</sub>), 133.3 (2 C<sub>qAr</sub>), 135.6 (C<sub>qAr</sub>), 140.6 (C<sub>qAr</sub>), 210.6 (C<sub>1</sub>).

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for  $C_{18}H_{26}O_2Na$ : 297.1825, found 297.1823, [M + H] $^+$ : calcd. for  $C_{18}H_{27}O_2$ : 275.2006, found 275.2007.

m.p. = 61-64 °C

# 2-((2R,4r,6S)-2,6-dimethyltetrahydro-2H-pyran-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3n



2,6-Dimethyltetrahydro-2H-pyran-4-ol (33 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/Et<sub>2</sub>O, gradient 9/1 to 8/2) afforded the title compound **3n** as a yellow solid (34 mg, 45%, dr 80:20 - measured after purification).

#### Major isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  1.16 (d, J = 6.1, 6H, 2 Me), 1.47–1.62 (m, 4H, H<sub>3</sub>·), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.67–2.74 (m, 1H, H<sub>4</sub>·), 2.88 (d, J = 6.9, 2H, H<sub>2</sub>), 3.51–3.68 (m, 2H, H<sub>2</sub>·).

 $^{13}\text{C NMR (101 M, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{C}}\text{H}_3), \ 16.8 \ (\underline{\text{C}}\text{H}_3), \ 17.1 \ (2 \ \underline{\text{C}}\text{H}_3), \ 22.4 \ (2 \ \text{C}_{\text{Me}}), \ 26.2 \ (\text{C}_4'), \ 37.4 \ (\text{C}_3'), \ 48.3 \ (\text{C}_2), \ 68.7 \ (\text{C}_{2'}), \ 127.3 \ (2 \ \text{C}_{\text{QAr}}), \ 133.3 \ (2 \ \text{C}_{\text{QAr}}), \ 135.6 \ (\text{C}_{\text{QAr}}), \ 140.7 \ (\text{C}_{\text{QAr}}), \ 210.7 \ (\text{C}_1).$ 

# Minor isomer:

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.83–0.97 (m, 2H, H<sub>3'</sub>), 1.21 (d, J = 6.2, 6H, 2 Me), 1.79–1.84 (m, 2H, H<sub>3'</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.19 (s, 6H, 2 CH<sub>3</sub>), 2.24 (s, 3H, CH<sub>3</sub>), 2.27–2.43 (m, 1H, H<sub>4'</sub>), 2.59 (d, J = 6.5, 2H, H<sub>2</sub>), 3.51–3.68 (m, 2H, H<sub>2'</sub>).

 $^{13}\text{C NMR (101 M, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{C}}_{\text{H}_3}), \ 16.8 \ (\underline{\text{C}}_{\text{H}_3}), \ 17.1 \ (2 \ \underline{\text{C}}_{\text{H}_3}), \ 22.2 \ (2 \ \text{C}_{\text{Me}}), \ 30.3 \ (\text{C}_4'), \ 39.7 \ (\text{C}_3'), \ 52.5 \ (\text{C}_2), \ 73.2 \ (\text{C}_{2'}), \ 127.3 \ (2 \ \text{C}_{\text{QAr}}), \ 133.3 \ (2 \ \text{C}_{\text{QAr}}), \ 135.6 \ (\text{C}_{\text{QAr}}), \ 140.6 \ (\text{C}_{\text{QAr}}), \ 210.7 \ (\text{C}_1).$ 

MS (ESI/HRMS)  $[M + Na]^+$ : calcd. for  $C_{20}H_{30}O_2Na$ : 325.2138, found 325.2137,  $[M + H]^+$ : calcd. for  $C_{20}H_{29}O_2$ : 303.2319, found 303.2317.

m.p. = 110-111 °C

# 2-(1-Benzylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5a



1-Benzylpyrrolidin-3-ol (177 mg, 1.0 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 8/2) afforded the title compound **5a** as a brownish solid (229 mg, 60%).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.48 (app dq, J = 13.3, 7.0, 1H, H<sub>4′</sub>), 2.08 (s, 6H, 2 CH<sub>3</sub>), 2.13–2.21 (m, 1H H<sub>4′</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.24–2.32 (app t, J = 7.3, 1H, H<sub>2′</sub>), 2.60 (t, J = 7.0, 2H, H<sub>5′</sub>), 2.70–2.88 (m, 3H, H<sub>3′</sub>, H<sub>2</sub>), 2.89 (dd, J = 9.3, 7.3, 1H, H<sub>2′</sub>), 3.59 (d, J = 12.9, 1H, CH<sub>2</sub>Ph), 3.68 (d, J = 12.9, 1H, CH<sub>2</sub>Ph), 7.20–7.40 (m, 5H, H<sub>Ar</sub>).

 $^{13}\text{C NMR (101 MHz, CDCl}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{CH}}_3), \ 16.8 \ (\underline{\text{C}}_{\text{H}_3}), \ 17.3 \ (2 \ \underline{\text{C}}_{\text{H}_3}), \ 31.0 \ (C_{4'}), \ 32.3 \ (C_{3'}), \ 51.9 \ (C_2), \ 53.9 \ (C_{5'}), \ 60.1 \ (C_{2'}), \ 60.6 \ (\underline{\text{C}}_{\text{H}_2}\text{Ph}), \ 127.1 \ (\text{CH}_{\text{Ar}}), \ 127.4 \ (2 \ \text{C}_{\text{QAr}}), \ 128.4 \ (2 \ \text{CH}_{\text{Ar}}), \ 128.9 \ (2 \ \text{CH}_{\text{Ar}}), \ 133.2 \ (2 \ \text{C}_{\text{QAr}}), \ 135.5 \ (C_{\text{QAr}}), \ 140.5 \ (C_{\text{QAr}}), \ 211.4 \ (C_1).$ 

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{24}H_{32}NO$ : 350.2478, found 350.2467.

m.p. = 58-61 °C

# 2-(1-(4-Methylbenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5b




1-(4-Methylbenzyl)pyrrolidin-3-ol (48 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 85/15) afforded the title compound **5a** as a brown oil (32 mg, 35%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.47 (ddt, J = 12.5, 7.8, 6.2, 1H, H<sub>4′</sub>), 2.08 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.11–2.30 (2 masked m, 2H, H<sub>2′</sub>, H<sub>4′</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.34 (s, 3H, NBnCH<sub>3</sub>), 2.50–2.65 (m, 2H, 2 H<sub>5′</sub>) 2.66–2.84 (m, 3H, 2 H<sub>2</sub>, H<sub>3′</sub>), 2.89 (dd, J = 9.3, 7.3, 1H, H<sub>2′</sub>), 3.59 (AB system, J = 12.8, 2H, CH<sub>2</sub>Ar), 7.09–7.16 (d, J = 8.0, 2H, 2 H<sub>Ar</sub>), 7.18–7.24 (d, J = 8.0, 2H, 2 H<sub>Ar</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 21.2 (NBn<sub>C</sub>H<sub>3</sub>), 31.0 (C<sub>4</sub>'), 32.3 (C<sub>3</sub>'), 51.9 (C<sub>2</sub>), 53.8 (C<sub>5</sub>'), 60.1 (C<sub>2</sub>'), 60.3 (<u>C</u>H<sub>2</sub>Ar), 127.4 (2 C<sub>qAr</sub>), 128.9 (2 C<sub>HAr</sub>), 129.0 (2 C<sub>HAr</sub>), 133.2 (2 C<sub>qAr</sub>), 135.5 (C<sub>qAr</sub>), 136.1 (C<sub>qAr</sub>), 136.6 (C<sub>qAr</sub>), 140.6 (C<sub>qAr</sub>), 211.4 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{25}H_{34}NO$ : 364.2635, found 364.2634.

#### 2-(1-(3-Methoxybenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5c



1-(3-Methoxybenzyl)pyrrolidin-3-ol (52 mg, 0.25 mmol, 1.0 eq.) was subjected to procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 98:2) afforded the title compound **5c** as a brown oil (41 mg, 43%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.41 (app dq, J = 13.2, 7.0, 1H, H<sub>4′</sub>), 2.00 (s, 6H, 2 CH<sub>3</sub>), 2.06–2.13 (m, 7H, 2 CH<sub>3</sub>, H<sub>4′</sub>), 2.14 (s, 3H, CH<sub>3</sub>), 2.19–2.32 (m, 1H, H<sub>2′</sub>), 2.54 (app t, J = 7.0, 2H, 2 H<sub>5′</sub>), 2.62–2.71 (m, 1H, H<sub>3′</sub>), 2.71–2.76 (m, 2 H, H<sub>2</sub>), 2.77–2.88 (m, 1H, H<sub>2′</sub>), 3.54 (AB system, J = 13.0, 2H, CH<sub>2</sub>Ar), 3.73 (s, 3H, OMe), 6.68–6.75 (m, 1H, H<sub>Ar</sub>), 6.81–6.86 (m, 2H, 2 H<sub>Ar</sub>), 7.10–7.20 (m, 1H, H<sub>Ar</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.3 (2 CH<sub>3</sub>), 31.0 (C<sub>4</sub>′), 32.3 (C<sub>3</sub>′), 51.8 (C<sub>2</sub>),53.9 (C<sub>5</sub>′), 55.3 (C<sub>OMe</sub>), 60.0 (C<sub>2</sub>′), 60.5 (<u>C</u>H<sub>2</sub>Ar), 112.7 (CH<sub>ArOMe</sub>), 114.4 (CH<sub>ArOMe</sub>), 121.3 (CH<sub>ArOMe</sub>), 127.4 (2 C<sub>qAr</sub>), 129.3 (CH<sub>ArOMe</sub>), 133.2 (2 C<sub>qAr</sub>), 135.5 (C<sub>qArOMe</sub>), 140.5 (C<sub>qArOMe</sub> and C<sub>qAr</sub>), 159.7 (C<sub>qArOMe</sub>), 211.4 (C<sub>1</sub>).

MS (ESI/HRMS) [M + Na]<sup>+</sup>: calcd. for  $C_{25}H_{33}NO_2Na$ : 402.2404, found 402.2397. [M + H]<sup>+</sup>: calcd. for  $C_{25}H_{34}NO_2$ : 380.2584 found 380.2581.

# 1-(2,3,4,5,6-Pentamethylphenyl)-2-(1-(4-(trifluoromethyl)benzyl)pyrrolidin-3-yl)ethanone 5d

1-(4-(Trifluoromethyl)benzyl)pyrrolidin-3-ol (61 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 98:2) afforded the title compound **5d** as a brown oil (55 mg, 53%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.48 (app dq, J = 13.0, 7.0, 1H, H<sub>4′</sub>), 2.07 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.15–2.21 (masked m, 1H, H<sub>4′</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.25–2.29 (m, 1H, H<sub>2′</sub>), 2.58 (app t, J = 7.0, 2H, H<sub>5′</sub>), 2.68–2.83 (m, 3H, 2 H<sub>2</sub>, H<sub>3′</sub>), 2.86 (dd, J = 9.2, 7.3, 1H, H<sub>2′</sub>), 3.62 (d, J = 13.4, 1H, CH<sub>2</sub>Ar), 3.71 (d, J = 13.4, 1H, CH<sub>2</sub>Ar), 7.44 (d, J = 7.9, 2H, H<sub>Ar</sub>), 7.56 (d, J = 7.9, 2H, H<sub>Ar</sub>).


<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.3 (2 CH<sub>3</sub>), 31.0 (C<sub>4</sub>'), 32.4 (C<sub>3</sub>'), 51.9 (C<sub>2</sub>), 53.9 (C<sub>5</sub>'), 60.0 and 60.1 (<u>C</u>H<sub>2</sub>Ar and C<sub>2</sub>'), 124.4 (q, J = 272, CF<sub>3</sub>), 125.3 (q, J = 4, 2 C<sub>HAr</sub>), 127.4 (2 C<sub>qAr</sub>), 129.0 (2 C<sub>HAr</sub>), 129.3 (q, J = 32, C<sub>qAr</sub>), 133.2 (2 C<sub>qAr</sub>), 135.6 (C<sub>qAr</sub>), 140.5 (C<sub>qAr</sub>), 143.4 (C<sub>qAr</sub>), 211.4 (C<sub>1</sub>).

#### <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -62.4.

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{25}H_{31}F_3NO$ : 418.2352, found 418.2358.  $[M + Na]^+$ : calcd. for  $C_{25}H_{30}F_3NONa$ : 440.2172, found 440.2174.

m.p. = 61-65 °C

# 2-(1-(4-Fluorobenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5e



1-(4-Fluorobenzyl)pyrrolidin-3-ol (49 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash column chromatography (SiO<sub>2</sub>, DCM/MeOH, 96/4) afforded the title compound **5e** as a brownish oil (43 mg, 47%).


<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.44 (dtd, J = 13.1, 7.2, 5.9, 1H, H<sub>4</sub>'), 2.04 (s, 6H, 2 CH<sub>3</sub>), 2.13 (s, 6H, 2 CH<sub>3</sub>), 2.10–2.19 (m masked, 1H, H<sub>4</sub>'), 2.19 (s, 3H, CH<sub>3</sub>), 2.23 (dd, J = 9.4, 6.0, 1H, H<sub>2</sub>'), 2.55 (app t, J = 7.2, 2H, H<sub>5</sub>'), 2.64–2.79 (m, 3H, 2 H<sub>2</sub>, H<sub>3</sub>'), 2.84 (dd, J = 9.4, 7.5, 1H, H<sub>2</sub>'), 3.51 (d, J = 12.9, 1H, CH<sub>2</sub>Ph), 3.60 (d, J = 12.9, 1H, CH<sub>2</sub>Ph), 6.91–6.98 (m, 2H, 2 H<sub>Ar</sub>), 7.21–7.28 (m, 2H, 2 H<sub>Ar</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.0 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 30.9 (C<sub>4</sub>′), 32.3 (C<sub>3</sub>′), 51.8 (C<sub>2</sub>), 53.8 (C<sub>5</sub>′), 59.7 (<u>C</u>H<sub>2</sub>Ar), 60.0 (C<sub>2</sub>′), 115.1 (d, J = 21.2, 2 C<sub>HAr</sub>), 127.4 (2 C<sub>QAr</sub>), 130.4 (d, J = 7.9, 2 C<sub>HAr</sub>), 133.2 (2 C<sub>QAr</sub>), 134.7 (C<sub>QAr</sub>), 135.5 (C<sub>QAr</sub>), 140.5 (C<sub>QAr</sub>), 162.0 (d, J = 245, C<sub>QAr</sub>), 211.4 (C<sub>1</sub>).

# <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -116.1.

MS (ESI/HR) [M + Na] $^+$ : calcd. for C<sub>24</sub>H<sub>30</sub>FNONa: 390.2204, found 390.2205. [M + H] $^+$ : calcd. for C<sub>24</sub>H<sub>31</sub>FNO: 368.2384, found 368.2386.

# 1-(2,3,4,5,6-pentamethylphenyl)-2-(1-phenethylpyrrolidin-3-yl)ethanone 5f




1-Phenethylpyrrolidin-3-ol (47 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 98:2) afforded the title compound **5f** as a brown oil (42 mg, 46%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.51–1.67 (m, 1H, H<sub>4′</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.14–2.29 (masked m, 1H, H<sub>4′</sub>) 2.50–2.64 (m, 1H, H<sub>2′</sub>), 2.70–3.01 (m, 9H, H<sub>2</sub>, H<sub>3′</sub>, H<sub>5′</sub>, CH<sub>2</sub>CH<sub>2</sub>Ph, CH<sub>2</sub>CH<sub>2</sub>Ph), 3.13 (app t, J = 8.8, 1H, H<sub>2′</sub>), 7.17–7.25 (m, 3H, H<sub>Ph</sub>), 7.25–7.34 (m, 2H, H<sub>Ph</sub>).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.3 (2 CH<sub>3</sub>), 30.8 (C<sub>4</sub>'), 32.3 (C<sub>3</sub>'), 34.8 (CH<sub>2</sub>CH<sub>2</sub>Ph), 51.2 (C<sub>2</sub>), 54.1 (CH<sub>2</sub>CH<sub>2</sub>Ph), 58.2 (C<sub>5</sub>'), 59.7 (C<sub>2</sub>'), 126.5 (CH<sub>Ph</sub>), 127.4 (2 C<sub>QAr</sub>), 128.7 (2 CH<sub>Ph</sub>), 128.8 (2 CH<sub>Ph</sub>), 133.3 (2 C<sub>QAr</sub>), 135.7 (C<sub>QAr</sub>), 139.5 (C<sub>QPh</sub>), 140.2 (C<sub>QAr</sub>), 211.2 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{25}H_{34}NO$ : 364.2635, found 364.2636.  $[M + Na]^+$ : calcd. for  $C_{25}H_{33}NONa$ : 386.2454, found 386.2456.

# 2-(1-Benzyl-4-methylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5g



(3*R*,4*S*)-1-Benzyl-4-methylpyrrolidin-3-ol (22 mg, 0.12 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ru-MACHO**. Purification by flash column chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 98/2) afforded the title compound **5g** as a brownish oil (9 mg, 21%, dr 90:10 - *measured after purification*).

# Major isomer:

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.92 (d, J = 7.1, 3H, Me), 2.08 (s, 6H, 2 CH<sub>3</sub>), 2.08–2.18 (masked m, 1H, H<sub>5′</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.25–2.35 (m, 1H, H<sub>2′</sub>), 2.40–2.53 (m, 1H, H<sub>4′</sub>), 2.58–2.87 (m, 3H, H<sub>3′</sub>, 2 H<sub>2</sub>), 2.97 (dd, J = 9.3, 7.2, 1H, H<sub>5′</sub>), 3.21 (dd, J = 9.6, 6.6, 1H, H<sub>2′</sub>), 3.57–3.78 (m, 2H, CH<sub>2</sub>Ph), 7.20–7.38 (m, 5H, 5 H<sub>Ph</sub>).

 $^{13}\text{C NMR } \text{ (75 MHz, CDCl}_3\text{) } \delta \text{ 15.4 (C}_{Me}\text{), 16.1 (2 $\underline{\text{C}}$H}_3\text{), 16.8 ($\underline{\text{C}}$H}_3\text{), 17.3 (2 $\underline{\text{C}}$H}_3\text{), 34.1 (C}_4\text{'}\text{), 35.4 (C}_3\text{'}\text{), 46.0 (C}_2\text{), 59.9 (C}_2\text{'}\text{), 60.7 ($\underline{\text{C}}$H}_2\text{Ph}\text{), 61.6 (C}_5\text{'}\text{), 127.2 (CH}_P\text{h}\text{), 127.4 (2 $C_{\text{QAr}}\text{), 128.4 (2 $CH}_P\text{h}\text{), 129.0 (2 $CH}_P\text{h}\text{), 133.3 (2 $C_{\text{QAr}}\text{), 135.6 (C}_{\text{QAr}}\text{), 140.8 (C}_{\text{QAr}}\text{), 211.4 (C}_1\text{). }$ 


#### Minor isomer:

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.03 (d, J = 6.7, 3H, Me), 1.80–1.96 (m, 1H, H<sub>4</sub>′), 2.03 (s, 6H, 2 CH<sub>3</sub>), 2.13 (s, 6H, 2 CH<sub>3</sub>), 2.18 (s, 3H, CH<sub>3</sub>), 2.07–2.29 (masked m, 2H, H<sub>3</sub>′, H<sub>5</sub>′), 2.52–3.00 (m, 5H, 2 H<sub>2</sub>, 2 H<sub>2</sub>′, H<sub>5</sub>′), 3.55–3.77 (m, 2H, CH<sub>2</sub>Ph), 7.17–7.35 (m, 5H, H<sub>Ph</sub>).

 $^{13}\text{C NMR } (75 \text{ MHz, CDCI}_3) \ \delta \ 16.1 \ (2 \ \underline{\text{CH}}_3), \ 16.8 \ (\underline{\text{CH}}_3), \ 17.3 \ (2 \ \underline{\text{CH}}_3), \ 18.5 \ (C_{Me}), \ 38.8 \ (C_4'), \ 40.7 \ (C_3'), \ 50.7 \ (C_2), \ 59.9 \ (C_2'), \ 60.4 \ (\underline{\text{CH}}_2\text{Ph}), \ 61.5 \ (\underline{\text{C}}_{\text{F}}), \ 127.2 \ (\text{CH}_{\text{Ph}}), \ 127.4 \ (2 \ C_{\text{qAr}}), \ 128.5 \ (2 \ \text{CH}_{\text{Ph}}), \ 129.1 \ (2 \ \text{CH}_{\text{Ph}}), \ 133.2 \ (2 \ C_{\text{qAr}}), \ 135.6 \ (C_{\text{qAr or Ph}}), \ 140.5 \ (C_{\text{qAr or Ph}}), \ 211.6 \ (C_1).$ 

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for C<sub>25</sub>H<sub>33</sub>NONa: 386.2454, found 386.2460. [M + H] $^+$ : calcd. for C<sub>25</sub>H<sub>34</sub>NO: 364.2635, found 364.2641.

# 2-(1-Benzylpiperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5h [2075811-80-0]



1-Benzylpiperidin-4-ol (191 mg, 1.0 mmol, 1.0 eq.) was subjected to Procedure **B** using Ir-1. Purification by flash column chromatography ( $SiO_2$ , solid load, gradient pentane/ $Et_2O$ , 8/2 to 7/3) afforded the title compound **5h** as a yellow solid (270 mg, 74%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.24–1.41 (m, 2H, H<sub>3'</sub>), 1.80–1.88 (m, 2H, H<sub>3'</sub>), 2.09 (s, 6H, 2 CH<sub>3</sub>), 2.01–2.14 (masked m, 3H, H<sub>2'</sub>, H<sub>4'</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.61 (d, J = 6.5, 1H, H<sub>2</sub>), 2.89 (app dt, J = 12.0, 3.3, 1H, H<sub>2'</sub>), 3.52 (s, 2H, CH<sub>2</sub>Ph), 7.20–7.36 (m, 5H, H<sub>Ph</sub>).

 $^{13}C$  NMR (101 M, CDCl<sub>3</sub>)  $\delta$  16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.1 (2 CH<sub>3</sub>), 30.6 (C<sub>4</sub>′), 32.3 (C<sub>3</sub>′), 52.3 (C<sub>2</sub>), 53.8 (C<sub>2</sub>′), 63.6 (<u>C</u>H<sub>2</sub>Ph), 127.1 (<u>C</u>H<sub>Ph</sub>), 127.4 (2 C<sub>qPh</sub>), 128.3 (2 <u>C</u>H<sub>Ph</sub>), 129.4 (2 <u>C</u>H<sub>Ph</sub>), 133.2 (2 C<sub>qAr</sub>), 135.5 (C<sub>qAr</sub>), 140.7 (C<sub>qAr</sub>), 211.0 (C<sub>1</sub>). NMR spctra were consistent with the literature.  $^6$ 

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for C<sub>25</sub>H<sub>34</sub>NO: 364.2635, found 364.2632.

m.p. = 104-106 °C

# 2-(1-Benzylpiperidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethenone 5i




1-Benzylpiperidin-3-ol (48 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using Ir-1. Purification by flash column chromatography ( $SiO_2$ , solid load, gradient pentane/EtOAc, 95/5 to 8/2) afforded the title compound **5i** as a yellow solid (30 mg, 33%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.01–1.16 (m, 1H, H<sub>4</sub>'), 1.60–1.70 (m, 2H, 2 H<sub>5</sub>'), 1.83–2.03 (m, 2H, H<sub>4</sub>', H<sub>2</sub>'), 2.07 (s, 6H, 2 CH<sub>3</sub>), 2.05–2.15 (masked m, 1H, H<sub>6</sub>'), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.35–2.47 (m, 1H, H<sub>3</sub>'), 2.58 (dd, J = 18.7, 6.6, 1H, H<sub>2</sub>), 2.62–2.74 (m, 2H, H<sub>6</sub>', H<sub>2</sub>), 2.83 (bd, J = 10.9, 1H, H<sub>2</sub>'), 3.49–3.58 (d, J = 13.3, 1H, CH<sub>2</sub>Ph), 3.54 (d, J = 13.3, 1H, CH<sub>2</sub>Ph), 7.19–7.37 (m, 5H, H<sub>Ph</sub>).

<sup>13</sup>C NMR (101 M, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 24.7 (C<sub>5</sub>′), 30.9 (C<sub>3</sub>′ and C<sub>4</sub>′), 50.0 (C<sub>2</sub>), 54.0 (C<sub>6</sub>′), 59.7 (C<sub>2</sub>′), 63.5 ( $\underline{\text{CH}}_{2}\text{Ph}$ ), 127.0 (CH<sub>Ph</sub>), 127.4 (2 C<sub>qAr</sub>), 128.3 (2 CH<sub>Ph</sub>), 129.2 (2 CH<sub>Ph</sub>), 133.2 (2 C<sub>qAr</sub>), 135.4 (C<sub>qAr</sub>), 138.6 (C<sub>qPh</sub>), 140.8 (C<sub>qAr</sub>), 210.8 (C<sub>1</sub>).

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for C<sub>25</sub>H<sub>33</sub>NONa: 386.2454 found: 386.2457.

#### 2-(1-Benzyl-1,2,3,4-tetrahydroquinolin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5j




1-Benzyl-1,2,3,4-tetrahydroquinolin-4-ol (34 mg, 0.14 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1.** Purification by flash column chromatography (SiO<sub>2</sub>, solid load, pentane/EtOAc, 96:4) afforded the title compound **5j** as a brown oil (12 mg, 21%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.92 (m, 1H, H<sub>3</sub>·), 2.00 (s, 6H, 2 CH<sub>3</sub>), 2.10 (s, 6H, 2 CH<sub>3</sub>), 2.15 (s, 3H, CH<sub>3</sub>), 2.13–2.26 (m, 1H, H<sub>3</sub>·), 2.87 (dd,  $J = 19.1, 8.7, 1H, H_2$ ), 3.01 (dd,  $J = 19.1, 4.6, 1H, H_2$ ), 3.22–3.41 (m, 2H, 2 H<sub>2</sub>·), 3.60 (m, 1H, H<sub>4</sub>·), 4.36–4.45 (AB system,  $J = 17.3, 2H, C_{H2}Ph$ ), 6.44 (dd,  $J = 8.3, 1.1, 1H, H_{Ar}$ ), 6.51 (td,  $J = 7.4, 1.1, 1H, H_{Ar}$ ), 6.90 (ddd,  $J = 8.6, 7.4, 1.7, 1H, H_{Ar}$ ), 7.04 (dd,  $J = 7.4, 1.7, 1H, H_{Ar}$ ), 7.11–7.26 (m, 5H, 5 H<sub>Ph</sub>).

 $^{13}\text{C NMR } \ (75 \ \text{MHz}, \ \text{CDCl}_3) \ \delta \ 16.1 \ (2 \ \text{CH}_3), \ 16.8 \ (\text{CH}_3), \ 17.1 \ (2 \ \text{CH}_3), \ 27.0 \ (\text{C}_3'), \ 31.2 \ (\text{C}_4'), \ 46.1 \ (\text{C}_2'), \ 52.3 \ (\text{C}_2), \ 55.1 \ (\underline{\text{C}}\text{H}_2\text{Ph}), \ 111.3 \ (\underline{\text{C}}\text{H}_{Ar}), \ 116.2 \ (\underline{\text{C}}\text{H}_{Ar}), \ 125.1 \ (\text{C}_{\text{QAr}}), \ 126.7 \ (2 \ \underline{\text{C}}\text{H}_{\text{Ph}}), \ 127.0 \ (\underline{\text{C}}\text{H}_{Ar}), \ 127.5 \ (2 \ \text{C}_{\text{QAr}}), \ 127.7 \ (\underline{\text{C}}\text{H}_{\text{Ph}}), \ 128.8 \ (2 \ \underline{\text{C}}\text{H}_{\text{Ph}}), \ 133.3 \ (2 \ \text{C}_{\text{QAr}}), \ 135.6 \ (\text{C}_{\text{QAr}}), \ 138.8 \ (\text{C}_{\text{QPh}}), \ 140.5 \ (\text{C}_{\text{QAr}}), \ 145.1 \ (\text{C}_{\text{QAr}}), \ 210.3 \ (\text{C}_1).$ 

MS (ESI/HRMS) [M + Na] $^+$ : calcd. for C<sub>29</sub>H<sub>33</sub>NONa: 434.2454, found 434.2459, [M + H] $^+$ : calcd. for C<sub>29</sub>H<sub>34</sub>NO: 412.2635, found 412.2636.

# 1-(2,3,4,5,6-pentamethylphenyl)-2-(piperidin-4-yl)ethanone 5k



Piperidin-4-ol (25 mg, 0.25 mmol, 1.0 eq.) was subjected to Procedure **B** using **Ir-1**. Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 10/1 + 1% Et<sub>3</sub>N) afforded the title compound **5k** as a yellow solid (57 mg, 83%).


<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 1.25 (m, 2H, H<sub>4</sub>), 1.88 (m, 2H, H<sub>4</sub>), 2.07 (s, 6H, 2 CH<sub>3</sub>), 2.09–2.20 (m, 1H, H<sub>3</sub>), 2.18 (s, 6H, 2 CH<sub>3</sub>), 2.23 (s, 3H, CH<sub>3</sub>), 2.66 (m, 2H, H<sub>2</sub>), 2.73 (m, 2H, H<sub>5</sub>), 3.10 (dt, J = 12.7, 3.3, 2H, H<sub>5</sub>).

 $^{13}\text{C}$  NMR (101 MHz, CD<sub>3</sub>OD)  $\delta$  16.0 (2 CH<sub>3</sub>), 16.7 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 31.9 (C<sub>3</sub>), 32.8 (C<sub>4</sub>), 46.6 (C<sub>5</sub>), 53.2 (C<sub>2</sub>), 128.1 (C<sub>qAr</sub>), 134.1 (C<sub>qAr</sub>), 136.4 (C<sub>qAr</sub>), 141.5 (C<sub>qAr</sub>), 213.3 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{18}H_{28}NO$ : 274.2165, found 274.2165.

m.p. = 173-177 °C

# 2-(1-(2-Fluorobenzyl)pyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5l



1,2,4-Butanetriol (133 mg, 1.2 mmol, 1.2 eq.) was subjected to the Procedure  $\bf C$  using (2-fluorophenyl)methanamine (114  $\mu$ L, 1.0 mmol, 1.0 eq.) Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 96:4) afforded the title compound  $\bf 5I$  as a brown oil (73 mg, 20%).


<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.38–1.62 (m, 1H, H<sub>4</sub>′), 2.07 (s, 6H, 2 CH<sub>3</sub>), 2.13–2.21 (m masked, 1H, H<sub>4</sub>′), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.28–2.40 (m, 1H, H<sub>2</sub>′), 2.59–2.84 (m, 5H, 2 H<sub>2</sub>, H<sub>3</sub>′, 2 H<sub>5</sub>′), 2.91–3.01 (m, 1H, H<sub>2</sub>′), 3.72 (bs, 2H, CH<sub>2</sub>Ar), 7.02 (ddd,  $J = 9.6, 8.1, 1.3, 1H, H_{Ar}$ ), 7.10 (td,  $J = 7.4, 1.3, 1H, H_{Ar}$ ), 7.22 (m, 1H, H<sub>Ar</sub>), 7.41 (t,  $J = 7.4, 1H, H_{Ar}$ ).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  16.0 (2 CH<sub>3</sub>), 16.7 (CH<sub>3</sub>), 17.2 (2 CH<sub>3</sub>), 30.9 (C<sub>4</sub>′), 32.3 (C<sub>3</sub>′), 51.7 (C<sub>2</sub>), 52.5 (<u>C</u>H<sub>2</sub>Ar), 53.6 (C<sub>5</sub>′), 59.8 (C<sub>2</sub>′), 115.3 (d, J = 22.2, <u>C</u>H<sub>Ar</sub>), 124.1 (d, J = 3.8, <u>C</u>H<sub>Ar</sub>), 124.9 (d, J = 15.3, C<sub>QAr</sub>), 127.4 (2 C<sub>QAr</sub>), 128.8 (d, J = 8.3, <u>C</u>H<sub>Ar</sub>), 131.5 (d, J = 4.0, <u>C</u>H<sub>Ar</sub>), 133.2 (2 C<sub>QAr</sub>), 135.5 (C<sub>QAr</sub>), 140.4 (C<sub>QAr</sub>), 161.2 (d, J = 246, C<sub>QAr</sub>), 211.4 (C<sub>1</sub>).

#### <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -118.3.

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{24}H_{31}FNO$ : 368.2384, found, 368.2383.

# 2-(1-Hexylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5m




1,2,4-Butanetriol (133 mg, 1.2 mmol, 1.2 eq.) was subjected to the Procedure  $\bf C$  using n-hexylamine (132  $\mu$ L, 1.0 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, DCM/MeOH, 96:4) afforded the title compound  $\bf 5m$  as a brown oil (137 mg, 40%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 0.84–0.93 (m, 3H, Me), 1.22–1.37 (m, 6H, 3 CH<sub>2</sub>), 1.43–1.57 (m, 3H, H<sub>4</sub>', C<u>H</u><sub>2</sub>), 2.09 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.13–2.21 (masked m, 1H, H<sub>4</sub>'), 2.22 (s, 3H, CH<sub>3</sub>), 2.27–2.37 (m, 1H, H<sub>2</sub>'), 2.37–2.57 (m, 2H, C<u>H</u><sub>2</sub>), 2.58–2.65 (m, 2H, H<sub>5</sub>'), 2.66–2.79 (m, 1H, H<sub>3</sub>'), 2.81–2.86 (m, 2H, H<sub>2</sub>), 2.96 (dd, J = 9.5, 7.8, 1H, H<sub>2</sub>').

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  14.2 (C<sub>Me</sub>), 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.3 (2 CH<sub>3</sub>), 22.8 (CH<sub>2</sub>), 27.5 (CH<sub>2</sub>), 28.7 (CH<sub>2</sub>), 31.0 (C<sub>4</sub>′), 31.9 (CH<sub>2</sub>), 32.3 (C<sub>3</sub>′), 51.8 (C<sub>2</sub>), 54.2 (C<sub>5</sub>′), 56.8 (CH<sub>2</sub>), 60.1 (C<sub>2</sub>′), 127.4 (2 C<sub>QAr</sub>), 133.2 (2 C<sub>QAr</sub>), 135.6 (C<sub>QAr</sub>), 140.5 (C<sub>QAr</sub>), 211.4 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{23}H_{38}NO$ : 344.2948, found, 344.2949.

# 2-(1-(4-Fluorobenzyl)piperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5n



1,3,5-Pentanetriol (144 mg, 1.2 mmol, 1.2 eq.) was subjected to the Procedure  $\bf C$  using (4-fluorophenyl)methanamine (115  $\mu$ L, 1.0 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, solid load, DCM/MeOH, 96:4) afforded the title compound  $\bf 5n$  as a brown solid (243 mg, 64%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.31 (app qd, J = 12.1, 4.4, 2H, 2 H<sub>3′</sub>), 1.79–1.89 (m, 2H, 2 H<sub>3′</sub>), 2.02 (dd, J = 11.8, 2.5, 2H, 2 H<sub>2′</sub>), 2.06–2.14 (m, 1H, H<sub>4′</sub>), 2.08 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.61 (d, J = 6.5, 2H, H<sub>2</sub>), 2.85 (m, 2H, 2 H<sub>2′</sub>), 3.45 (s, 2H, CH<sub>2</sub>Ar), 6.92–7.07 (app t, J = 8.8, 2H, 2 H<sub>Ar</sub>), 7.22–7.32 (m, 2H, 2 H<sub>Ar</sub>).


<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 16.1 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.1 (2 CH<sub>3</sub>), 30.7 (C<sub>4</sub>′), 32.4 (2 C<sub>3</sub>′), 52.3 (C<sub>2</sub>), 53.7 (2 C<sub>2</sub>′), 62.8 (<u>C</u>H<sub>2</sub>Ar), 115.1 (d,  ${}^2J_{CF}$  = 21, 2 CH<sub>Ar</sub>), 127.4 (2 C<sub>qAr</sub>), 130.8 (d,  ${}^3J_{CF}$  = 8, 2 CH<sub>Ar</sub>), 133.2 (2 C<sub>qAr</sub>), 134.4 (C<sub>qAr</sub>), 135.5 (C<sub>qAr</sub>), 140.8 (C<sub>qAr</sub>), 162.1 (d,  ${}^1J_{CF}$  = 245, C<sub>qAr</sub>), 210.9 (C<sub>1</sub>).

# <sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -116.2

MS (ESI/HRMS) [M + H] $^+$ : calcd. for C<sub>25</sub>H<sub>33</sub>FNO: 382.2541, found, 382.2538.

m.p. = 107-110 °C

#### 2-(1-Hexylpiperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 50



1,3,5-Pentanetriol (144 mg, 1.2 mmol, 1.2 eq.) was subjected to the Procedure  $\bf C$  using  $\it n$ -Hexylamine (131  $\it \mu L$ , 1.0 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 6/4 to 4/6) afforded the title compound  $\bf 5o$  as a brown oil (102 mg, 29%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.86-0.90 (m, 3H, CH<sub>3</sub>), 1.20–1.41 (m, 8H, 2 H<sub>3′</sub>, 3 CH<sub>2</sub>), 1.43–1.55 (m, 2H, CH<sub>2</sub>), 1.82–1.90 (m, 2H, 2 H<sub>3′</sub>), 1.95–2.07 (m, 3H, 2 H<sub>2′</sub>, H<sub>4′</sub>), 2.09 (s, 6H, 2 CH<sub>3</sub>), 2.17 (s, 6H, 2 CH<sub>3</sub>), 2.22 (s, 3H, CH<sub>3</sub>), 2.30–2.35 (m, 2H, CH<sub>2</sub>), 2.61 (d, J = 6.5, 2H, H<sub>2</sub>), 2.94 (dt, J = 12.0, 3.4, 2H, 2 H<sub>2′</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 14.2 (CH<sub>3</sub>), 16.0 (2 CH<sub>3</sub>), 16.8 (CH<sub>3</sub>), 17.1 (2 CH<sub>3</sub>), 22.7 (CH<sub>2</sub>), 27.1 (CH<sub>2</sub>), 27.5 (CH<sub>2</sub>), 30.7 (C<sub>4</sub>′), 31.9 (2 C<sub>3</sub>′), 32.3 (CH<sub>2</sub>), 52.4 (C<sub>2</sub>), 53.9 (2 C<sub>2</sub>′), 59.3 (CH<sub>2</sub>), 127.4 (2 C<sub>qAr</sub>), 133.2 (2 C<sub>qAr</sub>), 135.5 (C<sub>qAr</sub>), 140.7 (C<sub>qAr</sub>), 210.9 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{24}H_{40}NO$ : 358.3104, found, 358.3102.

# Ph\* Cleavage and post-functionalization

# 2-(Tetrahydrofuran-3-yl)acetic acid 6a [138498-97-2]




To a solution of 1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone 3a (65 mg, 0.25 mmol, 1.0 eq.) in HFIP (2.5 mL) in a MW vial, 200  $\mu$ L of 37% aqueous HCl was added dropwise to the solution and the vial was rapidly sealed with a cap. The reaction mixture was then heated at 65 °C in a preheated tray and stirred for 24 h. After complete conversion, the mixture was cooled to rt and  $H_2O$  (5 mL) was added. The solution obtained was further stirred for 5 min. The product was extracted with DCM (3 x 5 mL). The organic phases were combined and washed with brine (10 mL), dried over  $Na_2SO_4$ , filtered and concentrated under reduced pressure. Purification by flash column chromatography on silica gel (SiO<sub>2</sub>, pentane/Et<sub>2</sub>O, 2/8) afforded the title compound 6a as a colourless oil (22 mg, 69%).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 1.70–1.82 (m, 2H, H<sub>4</sub>'), 2.25 (dd, J = 17.1, 8.3, 1H, H<sub>2</sub>), 2.67 (dd, J = 17.1, 8.4, 1H, H<sub>2</sub>), 2.69–2.81 (m, 1H, H<sub>3</sub>'), 3.67–3.80 (m, 2H, H<sub>5</sub>'), 4.00 (dd, J = 9.1, 7.4, 1H, H<sub>2</sub>'), 4.48 (dd, J = 9.1, 7.3, 1H, H<sub>2</sub>').

<sup>13</sup>C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  33.3 (C<sub>3</sub>'), 34.5 (C<sub>2</sub>), 35.5 (C<sub>4</sub>'), 60.8 (C<sub>5</sub>'), 73.4 (C<sub>2</sub>'), 176.7 (C<sub>1</sub>).

MS (ESI/HR)  $[M + H]^+$ : calcd. for  $C_6H_{11}O_3$ : 131.0703, found 131.0702,  $[M + Na]^+$ : calcd. for  $C_6H_{10}O_3Na$ : 153.0522, found 153.0520.

#### N-(4-Methylbenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7a




1-(2,3,4,5,6-pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone **3a** (260 mg, 1.0 mmol, 1.0 eq.) was subjected to procedure **D** using p-methylbenzylamine (133  $\mu$ L, 1.0 mmol, 1.0 eq.). Purification by flash column chromatography (SiO<sub>2</sub>, pentane/EtOAc, 6/4 to 100% acetone) afforded N-(4-methylbenzyl)-2-(tetrahydrofuran-3-yl)acetamide **7a** as a brown to orange sticky oil (96 mg, 42%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.48–1.63 (m, 1H, H<sub>4'</sub>), 2.12 (m, 1H, H<sub>4'</sub>), 2.27 (d, J = 7.3, 2H, H<sub>2</sub>), 2.33 (s, 3H, Me), 2.69 (app hept, J = 7.3, 1H, H<sub>3'</sub>), 3.43 (dd, J = 8.6, 6.1, 1H, H<sub>2'</sub>), 3.69–3.87 (m, 2H, H<sub>5'</sub>), 3.87–3.94 (m, 1H, H<sub>2'</sub>), 4.38 (d, J = 5.6, 2H, CH<sub>2</sub>Ar), 5.80 (bs, 1H, NH), 7.08–7.20 (m, 4H, 4 H<sub>A'</sub>).

 $^{13}$ C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  21.2 ( $\underline{C}$ H<sub>3</sub>), 32.2 ( $C_{4'}$ ), 36.1 ( $C_{3'}$ ), 40.3 ( $C_{2}$ ), 43.5 ( $\underline{C}$ H<sub>2</sub>Ar), 67.8 ( $C_{5'}$ ), 73.1 ( $C_{2'}$ ), 127.9 (2 CH<sub>Ar</sub>), 129.5 (2 CH<sub>Ar</sub>), 135.3 ( $C_{qAr}$ ), 137.5 ( $C_{qAr}$ ), 171.5 ( $C_{1}$ ).

MS (ESI/HRMS) [M + H] $^+$ : calcd. for  $C_{14}H_{20}NO_2$ : 234.1489, found, 234.1490, [M + Na] $^+$ : calcd. for  $C_{14}H_{19}NO_2Na$ : 256.1308, found, 256.1310.

# N-(4-Iodobenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7b



1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone **3a** (78 mg, 0.30 mmol, 1.0 eq.) was subjected to procedure **D** using 4-iodobenzylamine (40  $\mu$ L, 0.30 mmol, 1.0 eq.). Purification by flash (SiO<sub>2</sub>, pentane/EtOAc, 4/6) afforded *N*-(4-iodobenzyl)-2-(tetrahydrofuran-3-yl)acetamide **7b** as yellowish crystals (30 mg, 29% overall yield).


<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.46–1.64 (m, 1H, H<sub>4</sub>), 2.02–2.19 (m, 1H, H<sub>4</sub>), 2.28 (d, J = 7.1, 2H, H<sub>2</sub>), 2.69 (app p, J = 7.1, 1H, H<sub>3</sub>), 3.42 (ddd, J = 7.8, 5.8, 1.6, 1H, H<sub>2</sub>), 3.74 (td, J = 8.7, 8.1, 7.1, 1H, H<sub>5</sub>), 3.79–3.94 (m, 2H, H<sub>2</sub>, H<sub>5</sub>), 4.35 (d, J = 5.8, 2H, CH<sub>2</sub>Ar), 5.92 (s, 1H, NH), 7.00 (d, J = 8.0, 2H, 2 H<sub>Ar</sub>), 7.64 (d, J = 8.0, 2H, 2 H<sub>Ar</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 32.2 (C<sub>4</sub>′), 36.1 (C<sub>3</sub>′), 40.2 (C<sub>2</sub>), 43.2 (<u>C</u>H<sub>2</sub>Ar), 67.8 (C<sub>5</sub>′), 73.0 (C<sub>2</sub>′), 93.0 (C<sub>qAr</sub>), 129.8 (2 C<sub>HAr</sub>), 138.10 (2 C<sub>HAr</sub>), 138.12 (C<sub>qAr</sub>), 171.6 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{13}H_{17}INO_2$ : 346.0299, found, 346.0294,  $[M + Na]^+$ : calcd. for  $C_{13}H_{16}INO_2Na$ : 368.0118, found, 368.0112.

m.p. = 102-105 °C

# N-(4-Methoxybenzyl)-2-(tetrahydrofuran-3-yl)acetamide 7c




1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone **3a** (78 mg, 0.30 mmol, 1.0 eq.) was subjected to procedure **D** using 4-methoxybenzylamine (39  $\mu$ L, 0.30 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 3/7) afforded the title compound **7c** as a brown oil (9 mg, 12% overall yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.41–1.58 (m, 1H, H<sub>4</sub>·), 2.05 (m, 1H, H<sub>4</sub>·), 2.20 (d, J = 7.3, 2H, H<sub>2</sub>), 2.63 (app hept, J = 7.3, 1H, H<sub>3</sub>·), 3.36 (dd, J = 8.6, 6.0, 1H, H<sub>2</sub>·), 3.73 (s, 3H, OMe), 3.61–3.81 (m, 2H, 2 H<sub>5</sub>·), 3.85 (dd, J = 8.6, 7.0, 1H, H<sub>2</sub>·), 4.29 (d, J = 5.6, 2H, CH<sub>2</sub>Ar), 5.67 (s, 1H, NH), 6.74–6.85 (d, J = 8.7, 2H, 2 H<sub>Ar</sub>), 7.07–7.23 (d, J = 8.7, 2H, 2 H<sub>Ar</sub>).

 $^{13}\text{C NMR (75 MHz, CDCl}_3) \ \delta \ 32.1 \ (\text{C}_4{}'), \ 36.0 \ (\text{C}_3{}'), \ 40.2 \ (\text{C}_2), \ 43.1 \ (\underline{\text{C}}\text{H}_2\text{Ar}), \ 55.3 \ (O\underline{\text{C}}\text{H}_3), \ 67.6 \ (\text{C}_5{}'), \ 72.9 \ (\text{C}_2{}'), \ 114.2 \ (\text{2 C}_{\text{HAr}}), \ 129.2 \ (\text{2 C}_{\text{HAr}}), \ 130.0 \ (\text{C}_{\text{qAr}}), \ 159.1 \ (\text{C}_{\text{qAr}}), \ 171.3 \ (\text{C}_1).$ 

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{14}H_{20}NO_3$ : 250.1438, found, 250.1436,  $[M + Na]^+$ : calcd. for  $C_{14}H_{19}NO_3Na$ : 272.1257, found, 272.1257.

#### N-Hexyl-2-(tetrahydrofuran-3-yl)acetamide 7d




1-(2,3,4,5,6-Pentamethylphenyl)-2-(tetrahydrofuran-3-yl)ethanone **3a** (78 mg, 0.30 mmol, 1.0 eq.) was subjected to procedure **D** using *n*-hexylamine (40  $\mu$ L, 0.30 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 3/7) afforded the title compound **7d** as a brown oil (15 mg, 23% overall yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.82–0.93 (m, 3H, CH<sub>3</sub>), 1.20–1.36 (m, 6H, 3 ((CH<sub>2</sub>)Hex), 1.41–1.52 (m, 2H, CH<sub>2</sub>Hex), 1.51–1.62 (m, 1H, H<sub>4'</sub>), 2.11 (m, 1H, H<sub>4'</sub>), 2.23 (d, J = 7.5, 2H, H<sub>2</sub>), 2.68 (app hept, J = 7.3, 1H, H<sub>3'</sub>), 3.23 (td, J = 7.2, 5.8, 2H, NHC $\underline{H}_2$ (CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub>), 3.42 (dd, J = 8.6, 6.0, 1H, H<sub>2'</sub>), 3.74 (dt, J = 8.5, 7.4, 1H, H<sub>5'</sub>), 3.81–3.89 (m, 1H, H<sub>5'</sub>), 3.90 (dd, J = 8.6, 6.9, 1H, H<sub>2</sub>), 5.52 (bs, 1H, NH).

 $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  14.1 ( $\underline{C}$ H<sub>3</sub>), 22.7 ( $\underline{C}$ H<sub>2</sub>), 26.7 ( $\underline{C}$ H<sub>2</sub>), 29.8 ( $\underline{C}$ H<sub>2</sub>), 31.6 ( $\underline{C}$ H<sub>2</sub>), 32.2 ( $\underline{C}$ <sub>4</sub>'), 36.2 ( $\underline{C}$ <sub>3</sub>'), 39.7 ( $\underline{C}$ H<sub>2</sub>), 40.4 ( $\underline{C}$ <sub>2</sub>), 67.8 ( $\underline{C}$ <sub>5</sub>'), 73.1 ( $\underline{C}$ <sub>2</sub>'), 171.6 ( $\underline{C}$ <sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{12}H_{24}NO_2$ : 214.1802, found, 214.1802,  $[M + Na]^+$ : calcd. for  $C_{12}H_{23}NO_2Na$ : 236.1621, found, 236.1620.

### 2-(4-Benzyltetrahydrofuran-3-yl)-N-benzylacetamide 7e




2-(4-Benzyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone **3l** (56 mg, 0.16 mmol, 1.0 eq. – **dr 59:41**) was subjected to procedure **D** using benzylamine (16  $\mu$ L, 0.14 mmol, 1.0 eq.). Purification by flash column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 6/4) afforded the title compound **7e** as a light orange sticky oil (26 mg, 53% overall yield, dr 53:47).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.09–2.29 (m, 2H, H<sub>4</sub>', CH<sub>2</sub>Ph, dia 1 and 2), 2.35–2.51 (m, 2H, H<sub>3</sub>', CH<sub>2</sub>Ph, dia 1 and 2), 2.57–2.73 (m, 2H, H<sub>4</sub>', H<sub>2</sub>, dia 1 and 2), 2.74–2.93 (m, 3H, H<sub>3</sub>', H<sub>2</sub>, dia 1 and 2), 3.46–3.58 (m, 3H, H<sub>2</sub>', H<sub>5</sub>', dia 1, H<sub>5</sub>', dia 2), 3.64 (dd, J = 8.6, 5.6, 1H, H<sub>2</sub>', dia 2), 3.76 (dd, J = 8.6, 6.6, 1H, H<sub>5</sub>', dia 2), 3.86 (dd, J = 8.9, 7.1, 1H, H<sub>5</sub>', dia 1), 3.98 (dd, J = 8.6, 6.6, 1H, H<sub>2</sub>', dia 2), 4.10 (dd, J = 8.9, 7.2, 1H, H<sub>2</sub>', dia 1), 4.39 (dd, J = 5.7, 3.9, 2H, CH<sub>2</sub>Ph, dia 2), 4.44 (d, J = 5.7, 2H, CH<sub>2</sub>Ph, dia 1), 5.62 (bs, 1H, dia 1), 5.77 (s, 1H, dia 2), 7.10–7.39 (m, 10H, H<sub>Ph</sub>, dia 1 and 2).

 $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  34.1 and 34.9 (CH<sub>2</sub>Ph, dia 1 and 2), 39.0 (C<sub>3′</sub>, dia 2), 39.3 and 40.2 (CH<sub>2</sub>Ph, dia 1 and 2), 42.1 (C<sub>3′</sub>, dia 1), 43.2 (C<sub>4′</sub>, dia 2), 43.8 and 43.9 (C<sub>2</sub>, dia 1 and 2), 46.9 (C<sub>4′</sub>, dia 1), 72.1 and 72.7 (C<sub>2′</sub> and C<sub>5′</sub>, dia 2), 73.1 and 73.5 (C<sub>2′</sub> and C<sub>5′</sub>, dia 1), 126.4 (CH<sub>Ar</sub>, dia 1 and 2), 127.8 (CH<sub>Ar</sub>, dia 1 and 2), 128.0 (2 CH<sub>Ar</sub>, dia 1 and 2), 128.7–128.9 (6 CH<sub>Ar</sub>, dia 1 and 2), 138.3 and 140.3 (C<sub>QAr</sub>, dia 1 and 2), 171.3 and 171.5 (C<sub>1</sub>, dia 1 and 2).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{20}H_{24}NO_2$ : 310.1802, found, 310.1801.  $[M + Na]^+$ : calcd. for  $C_{20}H_{23}NO_2Na$ : 332.1621, found, 332.1620.

### 2-(4-Benzyltetrahydrofuran-3-yl)-N-(4-methylbenzyl)acetamide 7f



2-(4-Benzyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone **3l** (48 mg, 0.14 mmol, 1.0 eq. – **dr 59:41**) was subjected to procedure **D** using 4-methylbenzylamine (18  $\mu$ L, 0.14 mmol, 1.0 eq.). Purification by flash column chromatography (SiO<sub>2</sub>, petroleum ether/EtOAc, 6/4) afforded the title compound **7f** as an orange solid (31 mg, 68% overall yield, dr 62:38).


<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.12–2.28 (m, 4H, H<sub>2</sub>, dia 1, 2 H<sub>2</sub>, H<sub>4</sub>', dia 2), 2.34 (s, 3H, CH<sub>3</sub>Ar, dia 1 and 2), 2.38–2.53 (m, 2H, H<sub>2</sub>, dia 1, H<sub>3</sub>', dia 2), 2.58–2.73 (m, 3H, H<sub>4</sub>', CH<sub>2</sub>Ph, dia 1 and dia 2), 2.73–2.91 (m, 3H, H<sub>3</sub>', CH<sub>2</sub>Ph, dia 1 and dia 2), 3.46–3.57 (m, 3H, H<sub>5</sub>', dia 1, H<sub>2</sub>', H<sub>5</sub>', dia 2), 3.64 (dd, J = 8.7, 5.6, 1H, H<sub>2</sub>', dia 1), 3.76 (dd, J = 8.5, 6.7, 1H, H<sub>5</sub>', dia 1), 3.86 (dd, J = 8.8, 7.2, 1H, H<sub>5</sub>', dia 2), 3.98 (dd, J = 8.7, 6.7, 1H, H<sub>2</sub>', dia 1), 4.06–4.15 (m, 1H, H<sub>2</sub>, dia 2), 4.35 (dd, J = 5.6, 4.2, 2H, CH<sub>2</sub>Ar, dia 2), 4.40 (d, J = 5.6, 2H, CH<sub>2</sub>Ar, dia 1), 5.51 (bs, 1H, NH, dia 2), 5.65 (bs, 1H, NH, dia 1), 7.08–7.35 (m, 18H, 8 H<sub>Ar</sub> and 10 H<sub>Ph</sub>, dia 1 and 2).

 $^{13}\text{C}$  NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  21.2 (CH<sub>3</sub>, dia 1 and 2), 34.0 (CH<sub>2</sub>Ph, dia 1), 34.9 (C<sub>2</sub>, dia 1), 39.0 (C<sub>3</sub>', dia 1), 39.2 (CH<sub>2</sub>Ph, dia 2), 40.1 (C<sub>2</sub>, dia 2), 42.1 (C<sub>3</sub>', dia 2), 43.2 (C<sub>4</sub>', dia 1), 43.5 (CH<sub>2</sub>Ar, dia 2), 43.6 (CH<sub>2</sub>Ar, dia 1), 46.8 (C<sub>4</sub>', dia 2), 72.0 (C<sub>5</sub>', dia 1), 72.7 (C<sub>2</sub>', dia 1), 73.1(C<sub>5</sub>', dia 2), 73.5 (C<sub>2</sub>', dia 2), 126.3 and 126.4 (C, dia 1 and 2), 128.0 (2 CH<sub>Ar</sub>, dia 1 and 2), 128.6 (2 CH<sub>Ph</sub>, dia 2), 128.7 (2 CH<sub>Ph</sub>, dia 1 and 2), 128.8 (CH<sub>Ph</sub>, dia 1 and 2), 129.6 (2 CH<sub>Ar</sub>, dia 1 and 2), 135.3 (C<sub>qAr</sub>, dia 1 and 2), 137.5 (C<sub>qAr</sub>, dia 1 and 2), 140.3 (C<sub>qPh</sub>, dia 1 and 2), 171.2 (C<sub>1</sub>, dia 2), 171.5 (C<sub>1</sub>, dia 1).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{21}H_{26}NO_2$ : 324.1958, found, 324.1959.  $[M + Na]^+$ : calcd. for  $C_{21}H_{25}NO_2Na$ : 346.1777, found, 346.1778.

m.p. = 104-107 °C

### (±)-N-(4-iodobenzyl)-2-((3R,4S)-4-propyltetrahydrofuran-3-yl)acetamide7g



1-(2,3,4,5,6-Pentamethylphenyl)-2-(4-propyltetrahydrofuran-3-yl)ethanone **3f** (91 mg, 0.30 mmol, 1.0 eq. – **dr 95:5**) was subjected to procedure **D** using 4-iodobenzylamine (70 mg, 0.30 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 6/4) afforded the title compound **7g** as yellow crystals (64 mg, 55% overall yield, dr 95:5).


<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 0.91 (t, J = 6.8, 3H, CH<sub>3</sub>), 1.16–1.39 (m, 4H, 2 CH<sub>2</sub>), 2.06 (dd, J = 14.7, 10.4, 1H, H<sub>2</sub>), 2.24–2.38 (m, 2H, H<sub>2</sub>, H<sub>4</sub>), 2.72 (app p, J = 5.5, 1H, H<sub>3</sub>), 3.42 (td, J = 8.1, 1.3, 1H, H<sub>5</sub>), 3.58 (ddd, J = 8.7, 3.9, 1.3, 1H, H<sub>2</sub>), 3.83–3.97 (m, 1H, H<sub>2</sub>), 4.26–4.49 (m, 2H, CH<sub>2</sub>Ar), 5.85 (bs, 1H, NH), 7.02 (d, J = 7.9, 2H, 2 H<sub>Ar</sub>), 7.65 (d, J = 7.9, 2H, 2 H<sub>Ar</sub>).

 $^{13}\text{C NMR (75 MHz, CDCl}_3) \ \delta \ 14.4 \ (\underline{\text{C}}_{\text{H}_3}), \ 21.8 \ (\underline{\text{C}}_{\text{H}_2}), \ 30.1 \ (\underline{\text{C}}_{\text{H}_2}), \ 34.6 \ (C_2), \ 38.7 \ (C_{3'}), \ 41.7 \ (C_{4'}), \ 43.3 \ (\underline{\text{C}}_{\text{H}_2}\text{Ar}), \ 72.2 \ (C_{5'}), \ 73.0 \ (C_{2'}), \ 93.1 \ (C_{\text{QAr}}), \ 129.9 \ (2 \ \text{CH}_{\text{Ar}}), \ 138.0 \ (2 \ \text{CH}_{\text{Ar}}), \ 138.1 \ (C_{\text{QAr}}), \ 172.0 \ (C_1).$ 

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{16}H_{23}INO_2$ : 388.0768, found, 388.0770.  $[M + Na]^+$ : calcd. for  $C_{16}H_{22}INO_2Na$ : 410.0587, found, 410.0590.

m.p. = 98-100 °C

# 2-((3R,6S)-6-Hydroxyhexahydrofuro[3,2-b]furan-3-yl)-N-(4-iodobenzyl)acetamide 7h




2-((3R,6S)-6-(tert-butoxy))hexahydrofuro[3,2-b]furan-3-y|)-1-(2,3,4,5,6-pentamethylphenyl)ethenone **3j** (100 mg, 0.28 mmol, 1.0 eq.) was subjected to procedure **D** using 4-iodobenzylamine (70 mg, 0.30 mmol, 1.1 eq.). Purification by flash chromatography (SiO<sub>2</sub>, pentane/EtOAc, 1/9) afforded the title compound **7h** as a brown oil (26 mg, 23% overall yield – dr > 99:1).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.31 (dd, J = 14.1, 6.2, 1H, H<sub>2</sub>), 2.48 (dd, J = 14.1, 8.9, 1H, H<sub>2</sub>), 2.57–2.74 (m, 1H, H<sub>3′</sub>), 3.31 (dd, J = 10.7, 8.2, 1H, H<sub>2′</sub>), 3.76–3.87 (m, 2H, 2 H<sub>5′</sub>), 4.03 (app t, J = 8.2, 1H, H<sub>2′</sub>), 4.26–4.31 (m, 1H, H<sub>6′</sub>), 4.34 (d, J = 11.0, 1H, CH<sub>2</sub>Ar), 4.36 (d, J = 11.0, 1H, CH<sub>2</sub>Ar), 4.41–4.49 (m, 1H, H<sub>6′a</sub>), 4.55–4.76 (m, 1H, H<sub>3′a</sub>), 6.27 (bs, 1H, NH), 7.01 (d, J = 8.4, 2H, 2 CH<sub>Ar</sub>), 7.64 (d, J = 8.4, 2H, 2 CH<sub>Ar</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  33.5 (C<sub>2</sub>), 42.4 (C<sub>3</sub>'), 43.2 (<u>C</u>H<sub>2</sub>Ar), 72.4 (C<sub>2</sub>'), 75.5 (C<sub>5</sub>'), 76.9 (C<sub>6</sub>'), 83.1 (C<sub>3</sub>'a), 89.2 (C<sub>6</sub>'a), 93.0 (C<sub>qAr</sub>), 129.8 (2 C<sub>HAr</sub>), 137.9 (2 C<sub>HAr</sub>), 138.1 (C<sub>qAr</sub>), 171.7 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{15}H_{19}INO_4$ : 404.0353, found, 404.0352.  $[M + Na]^+$ : calcd. for  $C_{15}H_{18}INO_4Na$ : 426.0173, found, 426.0171.

#### 2-(1-Benzylpyrrolidin-3-yl)-N-(4-methylbenzyl)acetamide 7i




2-(1-benzylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone **5a** (61 mg, 0.17 mmol, 1.0 eq.) was subjected to procedure **D** using 4-methylbenzylamine (22  $\mu$ L, 0.17 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, DCM/MeOH, 95/5) afforded the title compound **7i** as brown oil (22 mg, 40% overall yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.49 (ddd, J = 14.8, 10.3, 6.8, 1H, H<sub>4</sub>′), 1.92–2.13 (m, 1H, H<sub>4</sub>′), 2.25 (s, 3H, CH<sub>3</sub>), 2.27–2.74 (m, 7H, H<sub>2</sub>, H<sub>3</sub>′, H<sub>2</sub>′, H<sub>5</sub>′), 3.57 (AB system, J = 12.9, 2H, CH<sub>2</sub>Ph), 4.19–4.38 (m, 2H, CH<sub>2</sub>Ar), 6.50 (bs, 1H, NH), 6.86–7.31 (m, 9H, H<sub>Ar</sub>).

 $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  21.2 (CH<sub>3</sub>), 30.2 (C<sub>4</sub>′), 34.0 (C<sub>3</sub>′), 42.1 (C<sub>2</sub>), 43.4 (CH<sub>2</sub>Ar), 53.8 and 59.4 (C<sub>2</sub>′ and C<sub>5</sub>′), 60.2 (CH<sub>2</sub>Ph), 127.6 (CH<sub>Ar</sub>), 127.9 (2 CH<sub>Ar</sub>), 128.5 (2 CH<sub>Ar</sub>), 129.2 (2 CH<sub>Ar</sub>), 129.5 (2 CH<sub>Ar</sub>), 135.6 (C<sub>q</sub>Ar), 137.2 (C<sub>q</sub>Ar), 137.6 (C<sub>q</sub>Ar), 171.6 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{21}H_{27}N_2O$ : 323.2118, found, 323.2118.

### 2-(1-Benzylpiperidin-4-yl)-N-(4-methylbenzyl)acetamide 7j




2-(1-Benzylpiperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone **5h** (85 mg, 0.23 mmol, 1.0 eq.) was subjected to procedure **D** using 4-methylbenzylamine (30  $\mu$ L, 0.23 mmol, 1.0 eq.). Purification by flash chromatography (SiO<sub>2</sub>, DCM/MeOH, 95/5) afforded the title compound **7j** as brown sticky oil (26 mg, 34% overall yield).

<sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)  $\delta$  1.28–1.39 (m, 2H, H<sub>3</sub>'), 1.68–1.74 (m, 2H, H<sub>3</sub>'), 1.84-1.98 (m, 1H, H<sub>4</sub>'), 2.04 (app t, J = 11.5, 2H, H<sub>2</sub>'), 2.10 (d, J = 7.3, 2H, H<sub>2</sub>), 2.33 (s, 3H, CH<sub>3</sub>), 2.91 (d, J = 11.5, 2H, H<sub>2</sub>'), 3.54 (s, 2H, CH<sub>2</sub>Ph), 4.36 (d, J = 18.7, 2H, CH<sub>2</sub>Ar), 4.41 (d, J = 18.7, 1H, CH<sub>2</sub>Ar), 5.67 (bs, 1H, NH), 7.09–7.20 (m, 5H, H<sub>A</sub>r), 7.26–7.35 (m, 4H, H<sub>A</sub>r).

 $^{13}$ C NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  21.2 (CH<sub>3</sub>), 32.0 (2 C<sub>3′</sub>), 33.3 (C<sub>4′</sub>), 43.5 (CH<sub>2</sub>Ar), 43.9 (C<sub>2</sub>), 53.6 (2 C<sub>2′</sub>), 63.3 (CH<sub>2</sub>Ph), 127.4 (CH<sub>Ar</sub>), 128.0 (2 CH<sub>Ar</sub>), 128.4 (2 CH<sub>Ar</sub>), 129.4 (C<sub>QAr</sub>), 129.5 (4 CH<sub>Ar</sub>), 135.4 (C<sub>QAr</sub>), 137.4 (C<sub>QAr</sub>), 171.7 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{22}H_{29}N_2O$ : 337.2274, found, 337.2275.

### Methyl 2-(4-benzyltetrahydrofuran-3-yl)acetate 8a



2-(4-benzyltetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone **3l** (dr 89:11) (84 mg, 0.24 mmol, 1.0 eq.) was subjected to procedure **E** provided the title compound **8a** as a brown oil (24 mg, 43% overall yield, dr 87:13).

#### Major isomer:

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 2.33–2.91 (m, 6H, H<sub>2</sub>, H<sub>3</sub>', H<sub>4</sub>', CH<sub>2</sub>Ph), 3.58–3.69 (m, 2H, H<sub>2</sub>', H<sub>5</sub>'), 3.75 (s, 3H, OMe), 3.82 (dd, J = 8.6, 6.4, 1H, H<sub>5</sub>'), 4.07 (dd, J = 8.5, 6.7, 1H, H<sub>2</sub>'), 7.19–7.30 (m, 3H, H<sub>Ph</sub>), 7.31–7.39 (m, 2H, H<sub>Ph</sub>).

 $^{13}$ C NMR (75 MHz, CDCl<sub>3</sub>)  $\delta$  32.8 (C<sub>2</sub>), 33.8 (CH<sub>2</sub>Ph), 38.5 (C<sub>3</sub>′), 43.1 (C<sub>4</sub>′), 51.9 (C<sub>OMe</sub>), 72.0 (C<sub>5</sub>′), 72.8 (C<sub>2</sub>′), 126.3 (CH<sub>Ph</sub>), 128.7 (2 CH<sub>Ph</sub>), 128.8 (2 CH<sub>Ph</sub>), 140.3 (C<sub>q</sub>Ph), 173.2 (C<sub>1</sub>).

#### Minor isomer:

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  2.33–2.91 (m, 6H), 3.48–3.63 (m, 2H), 3.70 (s, 3H), 3.91 (dd, J = 8.8, 7.1, 1H), 4.16 (dd, J = 8.8, 7.1, 1H), 7.19–7.30 (m, 3H), 7.31–7.39 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 37.7 (1 C), 39.1 (1 C), 41.5 (1 C), 46.7 (1 C), 51.7 (COMe), 73.1 and 73.5 ( $C_{5'}/C_{2'}$ ), 126.4 (CH<sub>Ph</sub>), 128.7 (2 CH<sub>Ph</sub>), 128.8 (2 CH<sub>Ph</sub>), 140.2 (C<sub>QPh</sub>), 172.8 (C<sub>1</sub>).

MS (HRMS/ESI):  $[M+H]^+$ : calcd. for  $C_{14}H_{19}O_3$ : 235.1329 found 235.1328.  $[M+Na]^+$ : calcd. for  $C_{14}H_{18}O_3Na$ : 257.1148, found 257.1148.

#### Methyl 2-(1-benzylpyrrolidin-3-yl)acetate 8b [95274-12-7]




2-(1-Benzylpyrrolidin-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethenone **5a** (39 mg, 0.11 mmol, 1.0 eq.) was subjected to procedure **E** affording compound the title compound **8b** as a colorless oil (21 mg, 81%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.50–1.59 (m, 1H, H<sub>4</sub>'), 2.06–2.22 (m, 1H, H<sub>4</sub>'), 2.39 (dd, J = 9.6, 6.7, 1H, H<sub>2</sub>'), 2.41-2.47 (m, 2H, H<sub>2</sub>), 2.58–2.69 (m, 1H, H<sub>3</sub>'), 2.72 (t, J = 7.1, 2H, H<sub>5</sub>'), 2.94 (dd, J = 9.6, 7.7, 1H, H<sub>2</sub>'), 3.64 (s, 3H, OMe), 3.73 (s, 2H, CH<sub>2</sub>Ph), 7.23–7.40 (m, 5H, H<sub>Ph</sub>).

 $^{13}\text{C}$  NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  30.3 (C<sub>4'</sub>), 33.7 (C<sub>3'</sub>), 39.3 (C<sub>2</sub>), 51.7 (C<sub>Me</sub>), 53.6 (C<sub>5'</sub>), 59.3 (C<sub>2'</sub>), 60.1 (<u>C</u>H<sub>2</sub>Ph), 127.7 (C<sub>Ph</sub>), 128.6 (2 C<sub>Ph</sub>), 129.3 (2 C<sub>Ph</sub>), 137.0 (C<sub>qPh</sub>), 173.1 (C<sub>1</sub>).

MS (HRMS/ESI):  $[M+H]^+$ : calcd. for  $C_{14}H_{20}NO_2$ : 234.1489, found 234.1487.  $[M+H]^+$ : calcd. for  $C_{14}H_{19}NO_2Na$ : 256.1308, found 256.1309.

# Methyl 2-(1-Benzylpiperidin-4-yl)acetate 8c




1-Benzylpiperidin-4-ol (57 mg, 0.30 mmol, 1.0 eq.) was subjected to procedure **F** affording compound **8c** as a brown to yellow oil (66 mg, 89% overall yield).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 1.21–1.41 (m, 2H, 2 H<sub>3</sub>), 1.61–1.86 (m, 3H, H<sub>4</sub>', 2 H<sub>3</sub>'), 1.98 (td, J = 11.7, 2.5, 2H, 2 H<sub>2</sub>'), 2.23 (d, J = 7.0, 2H, H<sub>2</sub>), 2.81–2.91 (m, 2H, 2 H<sub>2</sub>'), 3.48 (s, 2H, CH<sub>2</sub>Ph), 3.66 (s, 3H, OCH<sub>3</sub>), 7.17–7.40 (m, 5H, 5 H<sub>Ph</sub>).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 32.2 (2 C<sub>3′</sub>), 33.0 (C<sub>4′</sub>), 41.1 (C<sub>2</sub>), 51.5 (OCH<sub>3</sub>), 53.6 (2 C<sub>2′</sub>), 63.5 (CH<sub>2</sub>Ph), 127.1 (C<sub>HPh</sub>), 128.3 (2 C<sub>HPh</sub>), 129.3 (2 C<sub>HPh</sub>), 138.6 (C<sub>QPh</sub>), 173.4 (C<sub>1</sub>).

MS (ESI/HRMS)  $[M + H]^+$ : calcd. for  $C_{15}H_{22}NO_2$ : 248.1645, found, 248.1646.

# 4-(2-Methoxy-2-oxoethyl)piperidinium chloride 8d [81270-37-3]




Piperidin-4-ol (30 mg, 0.30 mmol, 1.0 eq.) was subjected to procedure **F** affording compound **8d** as a yellow salt (44 mg, 76% overall yield).


<sup>1</sup>H NMR (400 MHz, MeOD- $d_4$ ) δ 1.49 (m, 2H, 2 H<sub>3</sub>), 1.93 (m, 2H, 2 H<sub>3</sub>), 2.01–2.13 (m, 1H, H<sub>4</sub>), 2.33 (d, J = 6.8, 2H, C $\underline{H}_2$ ), 2.98 (m, 1H, 2 H<sub>2</sub>), 3.33–3.39 (m, 2H, 2 H<sub>2</sub>), 3.64 (s, 3H, OC $\underline{H}_3$ ).

<sup>13</sup>C NMR (101 MHz, MeOD- $d_4$ )  $\delta$  29.4 (2 C<sub>3</sub>), 31.8 (C<sub>4</sub>), 40.7 (<u>C</u>H<sub>2</sub>), 45.0 (2 C<sub>2</sub>), 52.1 (<u>C</u>H<sub>3</sub>), 173.9 (CO).

MS (HRMS/ESI): [M+H]<sup>+</sup>: calcd. for C<sub>8</sub>H<sub>16</sub>NO<sub>2</sub>: 158.1176, found 158.1176.

# <sup>1</sup>H, <sup>13</sup>C and <sup>19</sup>F NMR spectra and Mass Analysis





# CENTRE COMMUN DE SPECTROMETRIE DE MASSE


#### Analysis Info


Analysis Name Impact2\_210324\_04\_JFR151.d Method Tune\_pos\_Standard.m

Acquisition Date 3/24/2021 2:03:32 PM Instrument / Ser# impact II 1825265.1 Comment 0081

Acquisition Parameter

ESI Ion Polarity Positive 0.3 Bar Source Type Set Nebulizer Set Capillary Set End Plate Offset Set Collision Cell RF 4500 V Set Dry Heater 200 °C Focus Active Scan Begin 50 m/z -500 V Set Dry Gas 4.0 Vmin 1000 m/z 750.0 Vpp Set Divert Valve Scan End Source





# CENTRE COMMUN DE SPECTROMETRIE DE MASSE


#### Analysis Info


Analysis Name Impact2\_2100924\_05\_JFR291.d

Acquisition Date Method Tune pos Standard.m 9/24/2021 2:26:31 PM Instrument / Ser# impact II Comment 1825265.1 0081

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Dry Heater Set Dry Gas Active 1500 V 200 °C Focus -500 V 750.0 Vpp Scan Begin 50 m/z 4.0 Vmin Scan End 1200 m/z Set Collision Cell RF Set Divert Valve Source





#### Analysis Info


Analysis Name Impact2\_210608\_01\_JFR210.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 6/8/2021 8:41:03 AM


 Comment
 Instrument / Ser# impact II
 1825265.1


## Acquisition Parameter

Positive 4500 V 0.3 Bar 200 °C Source Type ESI Ion Polarity Set Nebulizer Set Capillary Set End Plate Offset Set Dry Heater Set Dry Gas Set Divert Valve Active 50 m/z Focus Scan Begin -500 V 4.0 Vmin Scan End 500 m/z Set Collision Cell RF 200.0 Vpp Source



Bruker Compass DataAnalysis 5.2





-12.6

## Analysis Info

Analysis Name Impact2\_211014\_01\_JFR340.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 10/14/2021 10:09:30 AM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081

**Acquisition Parameter** 


Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset 4500 V -500 V 200 °C 4.0 Vmin Set Dry Heater Set Dry Gas Focus Active Scan Begin 50 m/z Scan End 1000 m/z Set Collision Cell RF 300.0 Vpp Set Divert Valve Source








mSigma Meas. m/z Ion Formula Sum Formula err [ppm] Adduct m/z Z 99.0804 M-H2O+H 99.0804 C6H11O C6H12O2 0.7 7.5 1+ 139.0728 C6H12NaO2 139.0730 8.0 4.1 M+Na 1+ 255.1566 C12H24NaO4 255.1567 0.2 26.2 2M+Na 1+

Bruker Compass DataAnalysis 5.2









#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Name Impact2 220214 02 JFR471.d Tune\_pos\_Standard.m Acquisition Date 2/14/2022 10:26:18 AM Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter ESI

Analysis Info

Method

Meas.m/z

153.0888

Ion Formula

C7H14NaO2


m/z

153.0886

Sum Formula

C7H14O2

Comment



err [ppm]

-1.6


mSigma


3.9

Adduct

M+Na

Z





## Analysis Info

Analysis Name Impact2\_211006\_07\_JFR326.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 10/6/2021 4:55:28 PM

 Comment
 Instrument / Ser# impact II
 1825265.1


 0081
 0081


Acquisition Parameter

Ion Polarity 0.3 Bar Source Type ESI Positive Set Nebulizer Focus Scan Begin Scan End Set Capillary Set End Plate Offset 4500 V -500 V 200 °C 4.0 Vmin Active Set Dry Heater 50 m/z 1200 m/z Set Dry Gas Set Divert Valve Set Collision Cell RF 750.0 Vpp Source



Bruker Compass DataAnalysis 5.2





## Analysis Info

0.4

0.2

0.0

192

193

Analysis Name Impact2\_211112\_11\_JFR370.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 11/12/2021 3:58:35 PM

 Comment
 Instrument / Ser#
 impact II
 1825265.1

 0081

## Acquisition Parameter

Source Type Ion Polarity ESI Positive 0.3 Bar Set Nebulizer Set Dry Heater Set Dry Gas Set Capillary Set End Plate Offset 1500 V 200 °C Active Focus Scan Begin 50 m/z -500 V 4.0 Vmin Set Collision Cell RF Scan End 1000 m/z 750.0 Vpp Set Divert Valve



 Meas. m/z
 Ion Formula
 m/z
 Sum Formula
 err [ppm]
 mSigma
 Adduct
 z

 193.1200
 C10H18NaO2
 193.1199
 C10H18O2
 -0.5
 1.0
 M+Na
 1+

194

1+

194.1233


195


196

197

m/z







#### Analysis Info

Analysis Name Impact2\_220406\_02\_JFR514.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 4/6/2022 4:36:20 PM

 Comment
 Instrument / Ser# impact II
 1825265.1


 0081
 0081

Acquisition Parameter

Ion Polarity Set Nebulizer Source Type ESI Positive 0.3 Bar Set Capillary Set End Plate Offset 4500 V -500 V Focus Scan Begin Scan End Set Dry Heater Set Dry Gas 200 °C 4.0 l/min Active 50 m/z 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source



Bruker Compass DataAnalysis 5.2



# Analysis Info


Analysis Name Impact2\_210702\_09\_JFR223.d

 Method
 LHCEP\_n5-.m
 Acquisition Date
 7/2/2021 2:45:48 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

Acquisition Parameter

Source Type Ion Polarity Positive Set Nebulizer 0.3 Bar ESI Set Capillary Set End Plate Offset Set Dry Heater Set Dry Gas Set Divert Valve 1000 V 200 °C Active 50 m/z Focus Scan Begin -500 V 4.0 Vmin Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Source



Sum Formula

C5H10O3

m/z

119.0703

141.0522

err [ppm]

0.1

0.2

mSigma

0.8

1.0

Adduct

M+H

M+Na

Z

1+

1+

Bruker Compass DataAnalysis 5.2

Ion Formula

C5H10NaO3


C5H11O3

Meas. m/z

119.0703

141.0522







## Analysis Info

Analysis Name Impact2 2100914 01 JFR294.d

Method Tune\_pos\_Standard.m Acquisition Date 9/14/2021 8:32:04 AM Instrument / Ser# impact II 1825265.1 Comment 0081 Acquisition Parameter Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset 3500 V -500 V 200 °C 4.0 Vmin Focus Scan Begin Active 50 m/z Set Dry Heater Set Dry Gas



Bruker Compass DataAnalysis 5.2



## Analysis Info

Analysis Name Impact2\_211118\_04\_JFR375.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 11/18/2021 1:24:45 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081

**Acquisition Parameter** 

ESI Ion Polarity Positive 0.3 Bar Set Nebulizer Source Type Set Dry Heater Set Dry Gas Set Capillary Set End Plate Offset 4500 V 200 °C Active Focus Scan Begin 50 m/z -500 V 4.0 Vmin Scan End 1000 m/z Set Collision Cell RF 300.0 Vpp Set Divert Valve Source



Sum Formula

C7H14O2

m/z

153.0886

Bruker Compass DataAnalysis 5.2

Ion Formula

C7H14NaO2

Meas. m/z

153.0887

Page 1 of 1

err [ppm]

-0.8


mSigma

4.9

Adduct

M+Na

Z



## CENTRE COMMUN DE SPECTROMETRIE DE MASSE Impact2 211125 02 JFR388.d Tune\_pos\_Standard.m Acquisition Date 11/25/2021 9:06:35 AM Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter

Set Nebulizer

195

196

m/z

0.3 Bar

Positive

Analysis Info Analysis Name

Method


Comment

Source Type

0

191

ESI




Ion Polarity

Ion Formula mSigma Sum Formula Meas. m/z err [ppm] Adduct m/z Z 192.1383 192.1384 C12H18NO C12H17NO -0.6 14.9 M+H 214.1203 C12H17NNaO 214.1202 -0.4 19.2 M+Na

193


194

192



#### Display Report Analysis Info Acquisition Date 8/24/2021 4:24:33 PM D:\Data\2021\2021\_08\Tama210824\_02\_JFR248.d Analysis Name tune esi.m Operator BDAL@DE Sample Name Default Instrument amaZon SL Comment Acquisition Parameter Ion Source Type Mass Range Mode Accumulation Time SPS Target Mass Alternating Ion Polarity Scan End Ion Polarity ESI Positive off Scan Begin RF Level 50 m/z 50 % 1000 m/z Enhanced Resolution 131 µs 250 m/z Trap Drive 5 Spectra n/a Averages n/a Intens. x10<sup>6</sup> Tama210824\_02\_JFR248.d: +MS, 0.1-0.4min #10-33 1+ 192.1 282.2 309.2 353.2 423.2 515.4 100 200 300 400 500 600 Intens +MS, 0.1-0.4min #10-33 x106 1+ 192.1 1+ 193.1 1+ 194.1 x10<sup>9</sup> C<sub>12</sub>H<sub>17</sub>NO, M+nH, 192.14 1+ 192.1 0.8 0.6-0.4 1+ 193.1 0.2-0.0 188 190 196 198 192 194 m/z

Bruker Compass DataAnalysis 4.2 printed: 8/24/2021 4:26:50 PM by: BDAL@DE Page 1 of 1




Analysis Name Impact2\_220214\_01\_JFR468.d Method Tune\_pos\_Standard.m


Acquisition Date 2/14/2022 10:21:35 AM Instrument / Ser# impact II 1825265.1

Acquisition Parameter

Analysis Info


Source Type Ion Polarity Positive Set Nebulizer 0.3 Bar 4500 V -500 V Focus Scan Begin Scan End Set Capillary Set End Plate Offset 200 °C 4.0 l/min Active Set Dry Heater 50 m/z Set Dry Gas 750.0 Vpp Set Divert Valve Source






Sum Formula C16H17NO mSigma Ion Formula Adduct err [ppm] Meas. m/z m/z Z C16H16N 222.1277 M-H2O+H 222,1277 0.3 26 1+ C16H18NO M+H 240.1382 240.1383 0.2 8.3 1+ C16H17NNaO 262.1203 262.1202 -0.3 20.4 M+Na 1+

Bruker Compass DataAnalysis 5.2







## Analysis Info


Analysis Name Impact2\_210201\_02\_JFR061-2.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 2/1/2021 8:22:45 AM


 Comment
 Instrument / Ser# impact II
 1825265.1

Acquisition Parameter

Source Type Ion Polarity ESI Positive 0.3 Bar Set Nebulizer Set Capillary Set End Plate Offset 1500 V 200 °C Set Dry Heater Focus Active Set Dry Gas Set Divert Valve Scan Begin 50 m/z -500 V 4.0 Vmin 750.0 Vpp Scan End 1000 m/z Set Collision Cell RF Source




Bruker Compass DataAnalysis 5.2




## Analysis Info

Analysis Name Impact2\_210409\_02\_JFR161-3.d

Method Tune\_pos\_Standard.m Acquisition Date 4/9/2021 8:07:54 AM Instrument / Ser# impact II Comment 1825265.1 0081 Acquisition Parameter Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Focus Active Set Capillary 1500 V Set Dry Heater 200 °C





## Analysis Info

Analysis Name Impact2\_2100924\_06\_JFR310.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 9/24/2021 2:42:15 PM


 Comment
 Instrument / Ser# impact II
 1825265.1


 0081
 0081

**Acquisition Parameter** 

Positive Source Type ESI Ion Polarity Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Focus Scan Begin Scan End 200 °C 4.0 Vmin Active 4500 V Set Dry Heater Set Dry Gas Set Divert Valve 50 m/z -500 V 1200 m/z Set Collision Cell RF 750.0 Vpp Source







## Analysis Info


Analysis Name Impact2\_210608\_02\_JFR214.d Method Tune pos Standard.m


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 6/8/2021 8:47:17 AM


 Comment
 Instrument / Ser# impact II
 1825265.1

Acquisition Parameter

Ion Polarity Set Capillary Set End Plate Offset Set Nebulizer Set Dry Heater Set Dry Gas Positive 4500 V 0.3 Bar 200 °C ESI Source Type Focus Active Scan Begin 50 m/z -500 V 4.0 Vmin 500 m/z Set Collision Cell RF 200.0 Vpp Scan End Set Divert Valve Source








# Analysis Info

Analysis Name Impact\_211028\_01\_JFR346.d
Method 210212 infusion cafeine 10 min.m
Comment


Acquisition Date 28/10/2021 09:10:38 Instrument / Ser# impact II 1825265.1

Acquisition Parameter


Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Focus Scan Begin Scan End Active 50 m/z 1500 V -500 V Set Dry Heater Set Dry Gas Set Divert Valve 200 °C 4.0 Vmin 1500 m/z Set Collision Cell RF 750.0 Vpp Source




Bruker Compass DataAnalysis 5.0



f1 (ppm)






#### Analysis Info

Analysis Name Impact2 220224 01 JFR476-2.d

Method Tune\_pos\_Standard.m Acquisition Date 2/24/2022 10:54:08 AM Instrument / Ser# impact II Comment 1825265.1 0001


#### Acquisition Parameter


Ion Polarity Set Capillary Positive 3000 V Set Nebulizer Set Dry Heater 0.3 Bar 200 °C Source Type Focus ESI Active Set Dry Gas Set Divert Valve Scan Begin 50 m/z Set End Plate Offset -500 V 4.0 l/min Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Source



627.4384 C40H60NaO4 627.4384 7.6 2M+Na -0.01+

Bruker Compass DataAnalysis 5.2






#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Impact2\_211012\_03\_JFR328.d Acquisition Date Tune pos Standard.m 10/12/2021 9:44:38 AM Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter Ion Polarity ESI Positive Set Nebulizer 0.3 Bar


Analysis Info Analysis Name


Method


Comment


Source Type















#### Analysis Info

Analysis Name Impact2\_211118\_03\_JFR376.d

Acquisition Date Method Tune pos Standard.m 11/18/2021 10:14:50 AM Instrument / Ser# impact II 1825265.1 Comment 0081

Acquisition Parameter


ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Source Type Active Set Capillary 4500 V Set Dry Heater 200 °C Focus Set End Plate Offset Set Collision Cell RF Scan Begin 50 m/z 1000 m/z -500 V Set Dry Gas 4.0 l/min 750.0 Vpp Scan End Set Divert Valve Source




Bruker Compass DataAnalysis 5.2

Page 1 of 1

1+





#### Analysis Info

Analysis Name Impact2\_220505\_09\_JFR520-2.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 5/5/2022 4:29:21 PM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081


**Acquisition Parameter** 

lon Polarity Set Capillary Set End Plate Offset Set Collision Cell RF 0.3 Bar 200 °C ESI Positive Set Nebulizer Source Type Set Dry Heater Set Dry Gas 1200 V Focus Active -500 V 750.0 Vpp Scan Begin Scan End 50 m/z 1000 m/z 4.0 l/min Set Divert Valve Source







Meas. m/z Ion Formula m/z Sum Formula err [ppm] mSigma Adduct Z 351.2317 C24H31O2 351.2319 C24H30O2 6.0 M+H 1+ 373.2137 C24H30NaO2 373.2138 0.3 5.3 M+Na 1+ C48H60NaO4 2M+Na 723.4384 723,4384 17.0 -0.0 1+



-10





-- 57.0

<  $\frac{17.1}{16.8}$  <  $\frac{16.8}{16.1}$ 

-211.0


#### Analysis Info

Analysis Name


Impact2\_210702\_10\_JFR225-2.d LHCEP\_n5-.m Method Acquisition Date 7/2/2021 2:52:23 PM Instrument / Ser# impact II Comment 1825265.1 0081


Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Collision Cell RF 200 °C 4.0 Vmin Focus Active 4500 V Set Dry Heater Scan Begin Scan End 50 m/z 1000 m/z -500 V Set Dry Gas Set Divert Valve 750.0 Vpp Source



Bruker Compass DataAnalysis 5.2







#### Analysis Info

Analysis Name Impact2\_2100916\_18\_JFR304-3.d

Source Type ESI Positive Set Nebulizer 0.3 Bar Ion Polarity Set Capillary Set End Plate Offset Set Collision Cell RF Active 1000 V Set Dry Heater 200 °C Focus Scan Begin 50 m/z -500 V Set Dry Gas 4.0 Vmin 750.0 Vpp Set Divert Valve Scan End 1000 m/z Source






 Meas. m/z
 Ion Formula
 m/z
 Sum Formula
 err [ppm]
 mSigma
 Adduct
 z

 304.2275
 C19H30NO2
 304.2271
 C19H29NO2
 -1.3
 2.8
 M+H
 1+

Bruker Compass DataAnalysis 5.2






#### Analysis Info


Analysis Name Impact2 210610 26 JFR207.d Method

Tune\_pos\_Standard.m Acquisition Date 6/10/2021 1:57:02 PM Instrument / Ser# impact II Comment 1825265.1 0081

Acquisition Parameter

0.3 Bar 200 °C 4.0 Vmin Source Type ESI Ion Polarity Positive Set Nebulizer Set Capillary Set End Plate Offset Set Collision Cell RF 1200 V -500 V Focus Scan Begin Active Set Dry Heater 50 m/z Set Dry Gas Set Divert Valve Scan End 1500 m/z 750.0 Vpp Source





-0.5

0.5

3.0

4.2

M+H

M+Na

1+

1+

Bruker Compass DataAnalysis 5.2

C18H27O2

C18H26NaO2


275.2007

297.1823

275.2006

297.1825

C18H26O2



#### Analysis Info

Analysis Name Impact2\_211125\_01\_JFR387.d Method Tune pos Standard.m


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 11/25/2021 9:04:39 AM

 Comment
 Instrument / Ser# impact II
 1825265.1


 0081

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Collision Cell RF Focus Active 4500 V Set Dry Heater 200 °C -500 V 750.0 Vpp Scan Begin 50 m/z 1200 m/z Set Dry Gas 4.0 Vmin Scan End Set Divert Valve Source



Bruker Compass DataAnalysis 5.2



110 100 f1 (ppm)

# Analysis Info


Analysis Name Impact2\_210324\_05\_JFR152-3.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 3/24/2021 2:15:00 PM


 Comment
 Instrument / Ser# impact II
 1825265.1


Acquisition Parameter


Source Type Ion Polarity ESI Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Dry Heater 200 °C 4500 V Focus Active Set Dry Gas Set Divert Valve Scan Begin 50 m/z -500 V 4.0 Vmin Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Source











#### Analysis Info

364.2634

C25H34NO

364.2635

C25H33NO


Analysis Name Impact2\_220720\_09\_JFR576.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 7/20/2022 3:08:42 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

**Acquisition Parameter** 


Positive 2000 V Source Type ESI Ion Polarity Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Collision Cell RF Set Dry Heater Set Dry Gas Set Divert Valve Focus 200 °C Active -500 V 750.0 Vpp 50 m/z 1000 m/z Scan Begin Scan End 4.0 l/min Source




0.2


M+H

4.0







JFR531-2.100.fid — no\_title



#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Info Analysis Name Impact2 220513 01 JFR531.d Acquisition Date 5/13/2022 8:01:15 AM Instrument / Ser# impact II 18252 Method Tune\_pos\_Standard.m Comment 1825265.1 Acquisition Parameter ESI Active 50 m/z Positive 1000 V Ion Polarity 0.3 Bar Set Capillary Set End Plate Offset 200 °C 4.0 Vmln







-10 -20 -30



-40 -50 -60 -70 -80 f1 (ppm)


-90 -100 -110 -120 -130 -140 -150 -160 -170 -180 -190 -2


#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Name Impact2\_220513\_04\_JFR543.d Tune\_pos\_Standard.m Acquisition Date 5/13/2022 8:17:16 AM Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter ESI Ion Polarity Set Nebulizer 0.3 Bar


Analysis Info


Method

Comment














#### Analysis Info

Analysis Name Impact2\_220520\_03\_JFR548.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 5/20/2022 11:19:58 AM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081


**Acquisition Parameter** 

Source Type Ion Polarity ESI Positive 0.3 Bar Set Nebulizer Set Dry Heater Set Dry Gas Active Set Capillary 1000 V 200 °C Focus Set End Plate Offset Set Collision Cell RF -500 V 750.0 Vpp Scan Begin 50 m/z 2000 m/z 4.0 Vmin Scan End Set Divert Valve Source





Meas. m/z Ion Formula Sum Formula err [ppm] mSigma Adduct m/z Z 368,2386 C24H31FNO 368,2384 C24H30FNO -0.4 52.3 M+H 1+ 34.4 390.2205 C24H30FNNaO -0.4 390.2204 M+Na 1+



Analysis Name Impact2\_220513\_03\_JFR542.d Method Tune pos Standard.m

Analysis Info

386.2456

C25H33NNaO

386.2454

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 5/13/2022 8:15:10 AM

 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081


 Acquisition Parameter

 Source Type
 ESI
 Ion Polarity
 Positive
 Set Nebulizer
 0.3 Bar

 Focus
 Active
 Set Capillary
 1000 V
 Set Dry Heater
 200 °C

 Scan Begin
 50 m/z
 Set End Plate Offset
 -500 V
 Set Dry Gas
 4.0 l/min

 Scan End
 1000 m/z
 Set Collision Cell RF
 750.0 Vpp
 Set Divert Valve
 Source





-0.4


52.9


M+Na

1+









110 100 f1 (ppm)

#### Analysis Info

Analysis Name Impact2\_211213\_01\_JFR403.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 12/13/2021 1:21:19 PM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081

**Acquisition Parameter** 

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Focus Scan Begin Scan End Set Capillary Set End Plate Offset Set Collision Cell RF 200 °C 4.0 l/min Active 1000 V Set Dry Heater 100 m/z 1000 m/z -500 V Set Dry Gas 750.0 Vpp Set Divert Valve Source






#### Analysis Info


Analysis Name Impact2\_210608\_03\_JFR217.d


Method Tune\_pos\_Standard.m Acquisition Date 6/8/2021 8:53:34 AM
Comment Instrument / Ser# impact II 1825265.1

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Focus Active Set Capillary 1500 V Set Dry Heater 200 °C Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 4.0 Vmin Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source







## Analysis Info

Analysis Name Impact2\_211117\_09\_JFR312.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 11/17/2021 1:44:06 PM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081

**Acquisition Parameter** 

Positive 1000 V Source Type ESI Ion Polarity Set Nebulizer 0.3 Bar Set Dry Heater Set Dry Gas Set Capillary Set End Plate Offset 200 °C 4.0 l/min Active 50 m/z Focus Scan Begin -500 V Scan End 1200 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source







Meas. m/z Ion Formula Sum Formula err [ppm] mSigma Adduct m/z Z 364.2635 -0.5 364.2637 C25H34NO C25H33NO M+H 5.5 1+ 386,2457 C25H33NNaO 386.2454 -0.77.2 M+Na 1+

Bruker Compass DataAnalysis 5.2

Page 1 of 1







110 10 f1 (ppm)

## Analysis Info

Analysis Name Impact2 220321 01 JFR496-2.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 3/21/2022 9:43:02 AM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0091


**Acquisition Parameter** 

Positive 4500 V -500 V Source Type ESI Ion Polarity Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Dry Heater Set Dry Gas 200 °C 4.0 l/min Focus Active Scan Begin 50 m/z Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source






err [ppm] Meas. m/z Ion Formula Sum Formula mSigma Adduct m/z Z 412.2635 412.2636 C29H34NO C29H33NO M+H -0.341.7 1+ 434,2459 C29H33NNaO 434.2454 M+Na -1.062.7 1+



#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Impact2 211012 01 JFR247.d Tune\_pos\_Standard.m Acquisition Date 10/12/2021 9:07:26 AM Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter ESI Ion Polarity Set Nebulizer



Bruker Compass DataAnalysis 5.2


Analysis Info Analysis Name

Method


Comment


Source Type

Page 1 of 1



S115





### Analysis Info


Analysis Name Impact2\_221003\_03\_JFR625-2.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 10/3/2022 10:50:20 AM

 Comment
 Instrument / Ser# impact II
 1825265.1

**Acquisition Parameter** 

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Focus Active Set Capillary 4500 V Set Dry Heater 200 °C Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 4.0 l/min Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source





## Analysis Info


Analysis Name Impact2\_230112\_06\_JFR726.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 1/12/2023 4:10:43 PM

 Comment
 Instrument / Ser#
 impact II
 1825265.1

Acquisition Parameter


Ion Polarity Positive 1500 V 0.3 Bar Source Type ESI Set Nebulizer Set Capillary Set End Plate Offset Set Dry Heater Set Dry Gas Active 200 °C Focus Scan Begin 50 m/z -500 V 4.0 l/min Scan End 1000 m/z Set Collision Cell RF 400.0 Vpp Set Divert Valve Source




×10<sup>5</sup> Impact2\_230112\_06\_JFR726.d: C23H38NO, 344.2948 1+ 344.2948 8 6 1+ 345.2981 2 1+ 346,3013 343 344 345 346 347 348 m/z

Meas. m/z Ion Formula Sum Formula mSigma Adduct m/z err [ppm] z C23H38NO 344,2948 344.2949 C23H37NO -0.2 20.1 M+H 1+


## 2-(1-(4-Fluorobenzyl)piperidin-4-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 5n









#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Info Impact2\_221018\_04\_JFR648.d Tune\_pos\_Standard.m Analysis Name Acquisition Date 10/18/2022 5:01:13 PM Method Comment Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Set Collision Cell RF Focus Active 3000 V Set Dry Heater 200 °C Scan Begin Scan End 50 m/z -500 V Set Dry Gas 4.0 l/min 1000 m/z 750.0 Vpp Set Divert Valve Source










0.5



#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Impact2 230202 01 JFR745.d Acquisition Date 2/2/2023 9:34:13 AM Tune\_pos\_Standard.m Instrument / Ser# Impact II 1825265.1 0081 Acquisition Parameter lon Polarity Set Capillary Set End Plate Offset Positive 4500 V -500 V 0.3 Bar 200 °C 4.0 l/min Set Nebulizer ESI Active

Analysis Info Analysis Name

Method


Comment


Source Type

Scan Begin

50 m/z

Focus





## Analysis Info

Analysis Name Impact2\_210824\_04\_JFR269-3.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 8/24/2021 4:30:37 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081


**Acquisition Parameter** 

Source Type Ion Polarity Positive Set Nebulizer 0.2 Bar Focus Scan Begin Scan End Set Capillary Set End Plate Offset Set Collision Cell RF 200 °C 4.0 l/min Active 4500 V Set Dry Heater 50 m/z Set Dry Gas Set Divert Valve -500 V 1200 m/z 750.0 Vpp Source



Bruker Compass DataAnalysis 5.2

Page 1 of 2




## Analysis Info

Analysis Name Impact2\_211208\_02\_JFR405.d


Method Tune\_pos\_Standard.m Acquisition Date 12/8/2021 12:58:39 PM Instrument / Ser# impact II 1825265.1 Comment 0081

Acquisition Parameter

ESI Ion Polarity Positive 0.3 Bar Set Nebulizer Source Type Set Dry Heater Set Dry Gas Set Capillary Set End Plate Offset 2500 V 200 °C Active Focus Scan Begin 50 m/z 4.0 Vmin Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source



234.1490 C14H20NO2 234,1489 C14H19NO2 -0.7 M+H 1.1 1+ 256,1310 C14H19NNaO2 256,1308 -0.7 3.7 M+Na 1+



## Analysis Info


Analysis Name Impact2\_220707\_02\_JFR573-2.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 7/7/2022 2:31:43 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

### **Acquisition Parameter**

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Focus Active Set Capillary 1000 V Set Dry Heater 200 °C Scan Begin 50 m/z Set End Plate Offset -500 V Set Dry Gas 4.0 l/min Scan End 1000 m/z Set Collision Cell RF 750.0 Vpp Set Divert Valve Source







#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Name Impact2\_220707\_01\_JFR580-2.d Acquisition Date 7/7/2022 2:25:41 PM Tune\_pos\_Standard.m Instrument / Ser# impact II 1825265.1 0081 Acquisition Parameter ESI Ion Polarity Set Nebulizer Positive 0.3 Bar

Analysis Info

Method

Comment





110 100 f1 (ppm)

## Analysis Info

Analysis Name Impact2\_220719\_01\_JFR583.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 7/19/2022 9:49:04 AM

 Comment
 Instrument / Ser# impact II
 1825265.1


**Acquisition Parameter** 


 Source Type
 ESI
 Ion Polarity
 Positive
 Set Nebulizer
 0.3 Bar

 Focus
 Active
 Set Capillary
 1000 V
 Set Dry Heater
 200 °C


 Scan Begin
 50 m/z
 Set End Plate Offset
 -500 V
 Set Dry Gas
 4.0 l/min


 Scan End
 1000 m/z
 Set Collision Cell RF
 750.0 Vpp
 Set Divert Valve
 Source





Meas. m/z	Ion Formula	m/z	Sum Formula	err [ppm]	mSigma	Adduct	Z
214.1802	C12H24NO2	214.1802	C12H23NO2	0.0	1.8	M+H	1+
236.1620	C12H23NNaO2	236.1621		0.3	5.7	M+Na	1+
449.3351	C24H46N2NaO4	449.3350		-0.3	9.3	2M+Na	1+





## Analysis Info


Analysis Name Impact2\_230208\_03\_JFR746.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 2/8/2023 11:30:28 AM


 Comment
 Instrument / Ser# impact II
 1825265.1


**Acquisition Parameter** 


Positive 1500 V Source Type Ion Polarity 0.3 Bar ESI Set Nebulizer Set Capillary Set End Plate Offset 200 °C 4.0 l/min Set Dry Heater Focus Active Scan Begin -500 V 50 m/z Set Dry Gas 750.0 Vpp 1000 m/z Scan End Set Collision Cell RF Set Divert Valve Source












Bruker Compass DataAnalysis 5.2




#### CENTRE COMMUN DE SPECTROMETRIE DE MASSE Analysis Name Impact2\_221025\_12\_JFR659.d Acquisition Date 10/25/2022 2:11:22 PM Tune\_pos\_Standard.m Instrument / Ser# impact II 1825265.1


Acquisition Parameter Ion Polarity Set Capillary Set End Plate Offset Set Collision Cell RF Set Nebulizer Set Dry Heater ESI Positive Source Type Focus 0.3 Bar Active 1000 V 200 °C Scan Begin Scan End 50 m/z 1000 m/z -500 V 750.0 Vpp Set Dry Gas 4.0 l/min Set Divert Valve Source


Analysis Info

Method

Comment









### Analysis Info

Analysis Name Impact2\_221025\_13\_JFR660.d


Acquisition Date 10/25/2022 2:19:04 PM Method Tune\_pos\_Standard.m Instrument / Ser# impact II 1825265.1 Comment


Acquisition Parameter Source Type ESI Source Type Focus Scan Begin Scan End ion Polarity Set Capillary Set End Plate Offset Positive Set Nebulzer 0.3 Bar Set Dry Heater Set Dry Gas Set Divert Valve Active 50 m/z 3000 V -500 V 200 °C 4.0 VmIn 1000 m/z Set Collision Cell RF 750.0 Vpp Source






Meas. m/z Ion Formula Sum Formula mSigma Adduct m/z err [ppm] Z 404.0352 C15H19INO4 404.0353 C15H18INO4 0.2 36.2 M+H 426.0171 C15H18INNaO4 426.0173 0.3 40.7 M+Na





 $\begin{array}{c} 4 & 4 & 4 & 4 & 3 & 3 \\ 4 & 2 & 3 & 4 & 4 & 4 & 3 & 3 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 & 2 & 2 & 2 \\ 4 & 2 &$ 



### Analysis Info


Analysis Name Impact2\_230208\_02\_JFR713.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 2/8/2023 11:27:32 AM

 Comment
 Instrument / Ser# impact II
 1825265.1

 Acquisition Parameter
 9081

Ion Polarity Source Type ESI Positive Set Nebulizer 0.3 Bar 200 °C 4.0 l/min Set Capillary Set End Plate Offset Focus Active 4500 V Set Dry Heater Scan Begin 50 m/z 1000 m/z -500 V Set Dry Gas 750.0 Vpp Set Collision Cell RF Scan End Set Divert Valve Source






err [ppm] Meas. m/z Ion Formula m/z Sum Formula mSigma Adduct z 323,2118 C21H27N2O 323,2118 C21H26N2O 0.0 8.4 M+H 1+

### 2-(1-Benzylpiperidin-4-yl)-N-(4-methylbenzyl)acetamide 7j






#### Analysis Info


Analysis Name Impact2\_221003\_04\_JFR631.d

 Method
 Tune\_pos\_Standard.m
 Acquisition Date Instrument / Ser#
 10/3/2022 10:59:37 AM impact II
 1825265.1

Acquisition Parameter


Positive 1000 V -500 V 0.3 Bar 200 °C 4.0 I/min ESI Ion Polarity Set Nebulizer Source Type Set Capillary Set End Plate Offset Focus Active Set Dry Heater Scan Begin Scan End 50 m/z Set Dry Gas Set Divert Valve 1000 m/z Set Collision Cell RF 750.0 Vpp Source





 Meas. m/z
 Ion Formula
 m/z
 Sum Formula
 err [ppm]
 mSigma
 Adduct
 z

 337.2275
 C22H29N2O
 337.2274
 C22H28N2O
 -0.2
 4.7
 M+H
 1+




#### Analysis Info


Analysis Name Impact2\_230403\_09\_JFR804-3.d

Acquisition Date 4/3/2023 5:24:31 PM Method Tune pos Standard.m Comment Instrument / Ser# impact II 1825265.1 0081

Acquisition Parameter

Ion Polarity Set Capillary Set End Plate Offset Set Collision Cell RF Set Nebulizer Set Dry Heater 0.3 Bar 200 °C Positive ESI Source Type 4500 V Focus Active Scan Begin Scan End 50 m/z 1000 m/z -500 V 750.0 Vpp Set Dry Gas 4.0 Vmin Set Divert Valve Source





#### Analysis Info

Analysis Name Impact2\_210702\_11\_JFR239.d


 Method
 LHCEP\_n5-.m
 Acquisition Date
 7/2/2021 3:41:19 PM

 Comment
 Instrument / Ser# impact II
 1825265.1

 9081


Acquisition Parameter

Source Type Ion Polarity ESI Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset 1000 V 200 °C Focus Active Set Dry Heater Scan Begin 50 m/z 500 V Set Dry Gas 4.0 Vmin Scan End Set Collision Cell RF 750.0 Vpp 1000 m/z Set Divert Valve Source



Bruker Compass DataAnalysis 5.2

Page 1 of 1





#### Analysis Info

Analysis Name Method Impact2\_220831\_01\_JFR595-OMe.d Tune\_pos\_Standard.m Acquisition Date 8/31/2022 4:55:14 PM Instrument / Ser# impact II 1825265.1 Comment 0081

Acquisition Parameter

Source Type ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Set Capillary Set End Plate Offset Focus Scan Begin Scan End 1500 V 200 °C 4.0 l/min Active Set Dry Heater 50 m/z 1000 m/z Set Dry Gas Set Divert Valve -500 V Set Collision Cell RF 750.0 Vpp Source





#### Analysis Info

Analysis Name Impact2\_220913\_05\_JFR605.d


 Method
 Tune\_pos\_Standard.m
 Acquisition Date
 9/13/2022 2:32:37 PM


 Comment
 Instrument / Ser# impact II
 1825265.1

 0081
 0081

Acquisition Parameter

ESI Ion Polarity Positive Set Nebulizer 0.3 Bar Source Type Set Capillary Set End Plate Offset Set Collision Cell RF Focus Active 4500 V Set Dry Heater 200 °C -500 V 300.0 Vpp Scan Begin 50 m/z 1000 m/z 4.0 Vmin Set Dry Gas Scan End Set Divert Valve Source





 Meas. m/z
 Ion Formula
 m/z
 Sum Formula
 err [ppm]
 mSigma
 Adduct
 z

 158.1176
 C8H16NO2
 158.1176
 C8H16NO2
 -0.5
 1.7
 M
 1+

# Single-Crystal X-ray diffraction

## (±)-2-((3R,4R)-4-Methoxytetrahydrofuran-3-yl)-1-(2,3,4,5,6-pentamethylphenyl)ethanone 3k


A suitable single-crystal of 3k was selected and mounted on an Xcalibur Gemini kappa-geometry diffractometer equipped with an Atlas CCD detector and a Copper X-ray source (I = 1.54184 Å). Intensities were collected at 150 K by means of the CrysalisPro software. Reflection indexing, unit-cell parameters refinement, Lorentz-polarization correction, peak integration and background determination were carried out with the CrysalisPro software. An analytical absorption correction was applied using the modeled faces of the crystal. The resulting set of hkl was used for structure solution and refinement. The structures were solved with the ShelXT9 structure solution program using the intrinsic phasing solution method and by using Olex210 as the graphical interface. The model was refined with version 2018/3 of ShelXL11 using least-squares minimization.

**CCDC 2243885** contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Date Centre via <a href="https://www.ccdc.cam.ac.uk/data">www.ccdc.cam.ac.uk/data</a> request/cif.

Table S1. Crystallographic Data Collection and Refinement Statistics

Compound	3k
Formula	$C_{18}H_{26}O_3$
$D_{calc.}$ / g cm <sup>-3</sup>	1.208
<i>m</i> /mm <sup>-1</sup>	0.638
Formula Weight	290.39
Colour	colourless
Shape	needle-shaped
Size/mm <sup>3</sup>	$0.47 \times 0.14 \times 0.10$
T/K	150.00(10)
Crystal System	monoclinic
Space Group	P2 <sub>1</sub> /c
a/Å	23.1710(9)
b/Å	7.8602(3)
c/Å	8.8261(3)
a/°	90
b/°	96.465(3)
g/°	90
V/Å <sup>3</sup>	1597.28(10)
Z	4
Z'	1
Wavelength/Å	1.54184
Radiation type	Cu K <sub>a</sub>
Q <sub>min</sub> /°	3.840
Q <sub>max</sub> /°	66.939
Measured Refl's.	32638
Indep't Refl's	2843
Refl's I≥2 s(I)	2571
R <sub>int</sub>	0.0623
Parameters	196
Restraints	2
Largest Peak	0.341
Deepest Hole	-0.254
GooF	1.024
$wR_2$ (all data)	0.1465
$wR_2$	0.1414
R₁ (all data)	0.0549
$R_1$	0.0512

Molecular view of  ${\bf 3k}$  with displacement ellipsoids plotted at the 30 % probability level.



## (±)-N-(4-iodobenzyl)-2-((3R,4S)-4-propyltetrahydrofuran-3-yl)acetamide7g


A suitable single-crystal of **7g** was selected and mounted on an Xcalibur Gemini kappa-geometry diffractometer equipped with an Atlas CCD detector and a Copper X-ray source (I = 1.54184 Å). Intensities were collected at 150 K by means of the CrysalisPro software. Reflection indexing, unit-cell parameters refinement, Lorentz-polarization correction, peak integration and background determination were carried out with the CrysalisPro software. An analytical absorption correction was applied using the modeled faces of the crystal. The resulting set of *hkl* was used for structure solution and refinement. The structures were solved with the ShelXT<sup>9</sup> structure solution program using the intrinsic phasing solution method and by using Olex2<sup>10</sup> as the graphical interface. The model was refined with version 2018/3 of ShelXL<sup>11</sup> using least-squares minimization.

**CCDC 2246522** contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Date Centre via <a href="https://www.ccdc.cam.ac.uk/data\_request/cif">www.ccdc.cam.ac.uk/data\_request/cif</a>.

**Table S2.** Crystallographic Data Collection and Refinement Statistics

7g C <sub>16</sub> H <sub>22</sub> INO <sub>2</sub> 1.584 15.506 387.24 colourless needle-shaped 0.47×0.03×0.01 100.00(10) triclinic P-1 9.6026(3) 10.9032(3) 15.9038(5) 80.907(3) 89.846(2) 80.988(2) 1623.48(9) 4 2 1.54184
Cu K <sub>a</sub> 5.385
76.996 47510
6462 5557 0.0971 363 0 2.091 -1.391 1.040 0.1555 0.1498 0.0634 0.0565

Molecular view of 7g with displacement ellipsoids plotted at the 30 % probability level.



- 1 P. J. Stevenson, Org. Biomol. Chem., 2011, **9**, 2078–2084.
- 2 M. Jacolot, S. Moebs-Sanchez and F. Popowycz, J. Org. Chem., 2018, 83, 9456–9463.
- 3 M. Larduinat, J. François, M. Jacolot and F. Popowycz, J. Org. Chem., 2023, 88, 7512-7517.
- 4 B. J. Stokes, S. M. Opra and M. S. Sigman, *J. Am. Chem. Soc.*, 2012, **134**, 11408–11411.
- 5 J. François, J. Rio, E. Jeanneau, M.-È. L. Perrin, M. Jacolot, P.-A. Payard and F. Popowycz, *Org. Chem. Front.*, 2023, **10**, 4732–4739.
- 6 W. M. Akhtar, C. B. Cheong, J. R. Frost, K. E. Christensen, N. G. Stevenson and T. J. Donohoe, *J. Am. Chem. Soc.*, 2017, **139**, 2577–2580.
- 7 Rigaku Oxford Diffraction, (2022), CrysAlisPro Software system, version 1.171.42.74a, Rigaku Corporation, Oxford, UK, .
- 8 R. C. Clark and J. S. Reid, *Acta Crystallogr A Found Crystallogr*, 1995, **51**, 887–897.
- 9 G. M. Sheldrick, Acta Crystallogr A Found Adv, 2015, 71, 3–8.
- 10 O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, J Appl Crystallogr, 2009, 42, 339–341.
- 11 G. M. Sheldrick, Acta Crystallogr C Struct Chem, 2015, 71, 3–8.